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ABBREVIATIONS 
 
aa, amino acid (only with numbers) 
Ab, antibody 
ADP, adesonise diphosphate 
Ag, antigen  
APC, antigen-presenting cell  
ATP, adenosine triphosphate 
APS, Ammonium peroxidisulfate 
A42: HLA-A2 restricted Melan-A/MART-1 
peptide-specific T cell clone 
bp, base pair (only with numbers)  
B-LCL: B-lymphoblastoid cell line 
BSA, bovine serum albumin  
CCR, C-C chemokine receptor  
CD, cluster of differentiation 
CHAPS: 3-((3-    
cholamidopropyl)dimethylammonio)-
1propanesulfonate; 
CML, cell-mediated lysis 
cpm, counts per minute  
CSF, colony-stimulating factor  
CTL, cytotoxic T lymphocyte  
CXCR, CXC chemokine receptor  
D3, Downscale 1:3 
DC, dendritic cell 
DIC, digital interference contrast 
DMSO, dimethylsulfoxide  
DNA, deoxyribonucleic acid  
DRiPs: defective ribosomal products 
ds, double-stranded (as dsDNA)  
ECL, enhanced chemiluminescence  
EDTA, ethylenediaminetetraacetic acid  
ELISA, enzyme-linked immunosorbent assay  ER, 
endoplasmic reticulum 
E:T ratio, effector to target ratio  
Fab, antigen-binding fragment of immunoglobulin 
FA, Formaldehyde 
FACS, fluorescence-activated cell sorter  
FCS, fetal calf serum  
FITC, fluorescein isothiocyanate   
FPLC, Fast Protein Liquid Chromatography 
g, gram (only with numbers)   
GM-CSF, granulocyte-macrophage CSF  
gp, glycoprotein (e.g., gp100)  
h, hour (only with numbers)  
HEPES, N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid  
HLA, human histocompatibility leukocyte antigens  
2-ME, 2-mercaptoethanol 
MFI: mean fluorescence intensity 
mg, milligram (only with numbers)  
MHC, major histocompatibility complex  
min, minute (only with numbers)  
ml, milliliter (only with numbers)  
mRNA, messenger RNA 
MyD88, myeloid differentiation factor 88 
µg, microgram (only with numbers)  
µl, microliter (only with numbers)  
m.w., molecular weight  
n, number in study or group  
MEM, non essential amino acids 
NF-kB, nuclear factor kB  
NK cell, natural killer cell  
NO, nitric oxide  
NS, not significant  
OVA, ovalbumin  
PAGE, polyacrylamide gel electrophoresis  
PBL, peripheral blood lymphocyte  
PBMC, peripheral blood mononuclear cell  
PBS, phosphate-buffered saline  
PCR, polymerase chain reaction  
PE, phycoerythrin  
PE, plating efficiency 
PFA, paraformaldehyde 
PG, prostaglandin  
PHA, phytohemagglutinin 
PI, propidium iodide 
PMA, phorbol myristate acetate  
PMSF, phenylmethylsulfonyl fluoride  
r, recombinant, (e.g., rIFN-g)  
rh-, recombinant human 
R, receptor (e.g., IL-2R) 
RCC: renal cell carcinoma 
RNA, ribonucleic acid  
rpm, revolutions per minute  
RT-PCR, reverse transcriptase polymerase    
chain reaction  
s.c., subcutaneous  
SD, standard deviation  
SDS, sodium dodecyl sulfate 
SEM, standard error of the mean 
SF, survival fraction 
TAA, tumor associated antigens 
TAP, transporter associated with antigen  
processing  
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HRP, horseradish peroxidase  
HSV, herpes simplex virus  
HSP: heat shock protein 
HSC70: constitutively expressed heat shock protein 
cognate 70 (Mr 73 kD) 
HSP70: inducible heat shock protein 70 (Mr 72 kD) 
HSP70-PC: HSP70/HSC70 peptide complexes  
HS: human serum 
IFN, interferon (e.g., IFN-g)  
Ig, immunoglobulin  
IL, interleukin (e.g., IL-2) 
IRAK, IL-1-receptor-associated kinase 
kDa, kilodalton (only with numbers) 
LAK-cells: Lymphokine-activated killer cells LPS, 
lipopolysaccharide  
mAb, monoclonal antibody 
MAPK, mitogen-activated protein kinase 
MART-1, melanoma antigen recognized by T cell 1 
TBS, Tris-buffered saline  
TBST, TBS with Tween 20  
TCA, trichloroacetic acid  
TCR, T cell receptor  
TEMED, tetramethylethylendiamine 
Th cell, T helper cell  
TGF, tumour growth factor 
TID, thermal isoeffect dose 
TIR, Toll/IL-1 receptor domain 
TLR, Toll-like receptor 
TMB, tetramethylbenzidine  
TNF, tumor necrosis factor  
TRAF6, TNF receptor-associated factor 6 
Tris, tris(hydroxymethyl)aminomethane 
Tyr, tyrosinase  
TyrF8: HLA-A2 restricted, tyrosinase peptide-
specific T cell clone 
VLE, very low endotoxin 
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1.1 THE CELLULAR ANTITUMOR IMMUNE RESPONSE: EFFECTOR CELLS 
AND MECHANISMS 
Host defense relies on a concerted action of both non-antigen specific innate immunity and 
antigen-specific adaptive immunity (Fearon et al. 1996; Medzhitov et al. 1997). Key features 
of the mammalian innate immune system include the ability (a) to rapidly recognize pathogen 
and/or tissue injury and (b) to signal the presence of danger to cells to the adaptive immune 
response (Matzinger 1994). The innate immune system is the very first inflammatory reaction 
and includes phagocytic cells, natural killer cells, complement and interferons. Evolutionary 
pressure has led to the development of the adaptive immunity, whose key features are (a) the 
ability to rearrange genes of the immunoglobulin family and the T cell receptor (TCR), 
permitting creation of a large diversity of antigen-specific clones and (b) antigen specific 
memory.  
1.1.1 Dendritic cells: the link between the innate and adaptive immune response 
The adaptive immune system is a highly sophisticated and potent system and needs to be 
instructed and regulated by antigen-presenting cells (APCs). Dendritic cells (DC) are unique 
APCs because they are the only ones that are able to induce primary immune responses, thus 
permitting the establishment of immunological memory (Banchereau et al. 1998). DC 
progenitors in the bone marrow give rise to circulating precursors that home to tissues, where 
they reside as immature cells with high phagocytic capacity. Following tissue damage, 
immature DCs capture antigen and subsequently migrate to the lymphoid organs, where they 
select rare antigen-specific T cells, whose TCR matches the antigenic ligand that DC had 
encountered. DCs directly present Ag to CD4+ T-helper cells, which regulate immune 
effectors, like B cells and NK cells and to Ag-specific CD8+ cytotoxic T cells. Morever, DCs 
prime CD8+ T cells to differentiate into effector cells and educate effector cells to home to 
the site of injury. DCs constitute a complex system of cells which, under different 
microenvironmental conditions, can induce contrasting states such as immunity and tolerance 
(Banchereau et al. 2000).  
1.1.2 Maturation of dendritic cells  
Immature DCs are defined by cell surface markers that represent functional capacity. They 
express the chemokine receptors CCR-1, CCR-2, CCR-5 and CXCR-1, commonly thought to 
allow DCs to migrate in response to inflammatory chemokines expressed by inflamed tissues. 
Immature DCs express the molecules CD1a, CD11 and the specific DC marker DC-specific 
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ICAM-3-grabbing nonintegrin DC-sign (CD209). Immature DCs are phagocytic and have a 
high level of macropinocytosis, allowing them to take up antigens. Expression of the FcgR1 
(CD64) and the mannose receptors allow efficient capture of IgG immune complexes and 
antigens that carry mannose or fucose residues. The high content of ER and endocytic 
compartments allows efficient antigen processing. If DCs receive inflammatory stimuli, DCs 
are remodeled. FcgR1 and mannose receptors are downregulated, resulting in a loss of 
endocytic activity and acidic intracellular compartments disappear. During this maturation 
process, the DC marker CD83 is induced, the levels of intracellular and surface MHC class II 
molecules, adhesion and costimulatory molecules are upregulated, and chemokine receptor 
expression changes. For example, the induced expression of CCR-7 on mature DCs allows 
them to home to T cell areas of secondary lymph nodes, where they present antigen to naive T 
cells and induce T cell differentiation to effector cells (Banchereau et al. 2000).  
In vitro human DC can be generated from peripheral blood mononuclear cells (PBMN) by 
adding GM-CSF and IL-4; addition of CD40L, LPS and TNF-a (“danger signal”) 
(Banchereau et al. 2000) (Matzinger 1994) to the culture on day 7 generates mature DCs 
(figure 1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Generation of human DC in vitro. To obtain immature DCs, blood monocytes are cultured in 
medium containing GM -CSF plus IL-4 for 7 days. The addition of TNF-a or LPS induces immature DCs to 
mature within 1 to 2 days. 
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1.1.3 DC/T cell interaction  
The ability to prime naïve CD4+ and CD8+ T cells constitutes a unique and critical function 
of DCs. This ability results from the expression of molecules unique to DCs, like the DC-
specific ICAM-3-grabbing nonintegrin (DC-Sign) or from the high density of molecules 
involved in the DC/T cell interaction, like costimulatory and adhesion molecules. MHC-
peptide complexes are 10 to 100-fold higher on DCs than on other APCs, like B cells or 
monocytes and macrophages.  
Priming of a naïve T cell requires two signals. Signal one is the recognition of MHC-peptide 
complexes on DCs by the Ag-specific TCRs on T cells. The second signal is the interaction 
of costimulatory molecules expressed by DCs (like CD86, CD80, CD40) and their ligands, 
CD28 and CD40L on T cells. Signal 1 and 2 must be provided by the same cell. T cells that 
receive both signals become activated and produce cytokines, proliferate and differentiate into 
effector cells. In the absence of CD28 ligation, T cells undergo apoptosis or become anergic. 
1.1.4 Antigen presentation  
T cells recognize antigens exclusively as peptides presented by MHC class I or II molecules. 
All nucleated cells are equipped with the machinery for endogenous antigen processing, 
leading to presentation by MHC class I molecules. The processing for MHC class II 
presentation (exogenous pathway) is restricted to antigen presenting cells (APC). Among 
APCs, DC are best equipped for both pathways and in addition may employ a third pathway, 
called cross-presentation. 
Soluble and particulate antigens are efficiently captured either through macropinocytosis or 
receptor-mediated endocytosis and they are subsequently degraded in endosomes (exogenous 
pathway). The generated peptides are usually 13-20 amino acids long. In immature DCs 
MHC II molecules are retained in a special compartment and have a short half- life on the cell 
surface due to rapid internalization. Inflammatory stimuli lead to DC maturation, resulting in 
a burst of class II synthesis and translocation of the MHC II-peptide complexes to the cell 
surface, where they remain stable for days and are available for recognition by CD4+ T cells 
(Adler et al. 1998) (figure 2). 
Antigens presented by MHC class I molecules are generally derived from intracellular 
proteins (self or foreign). They are degradated into peptides of 8-9 amino acids length and 
located into MHC class I classically via the endogenous pathway (Kurts et al. 1996) (figure 
2). Processing starts in the cytosol by the proteasomes. The peptides generated are transported 
to the endoplasmic reticulum (ER) by TAP (= transporter associated with antigen processing) 
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proteins in a ATP-dependent manner. Several ER-resident chaperones facilitate and control 
the loading of peptides into MHC class I molecules. Assembled peptide-MHC I complexes 
then move through the Golgi apparatus to the cell surface where they can be recognized by 
CD8+ T cells (figure 2).  
 
 
                 Endogenous                  Exogenous  
Figure 2: Antigen-processing pathways for the MHC class I and class II molecules. A) MHC class I 
molecules present peptides that are primarily derived from endogenously synthesized proteins of either self or 
pathogen origin. These proteins are degraded into peptides by the proteasome and then transported through the 
transporters of antigen-processing (TAP) molecules into the endoplasmic reticulum for loading on MHC class I 
molecules. B) By contrast, MHC class II molecules present proteins that enter the cell through the endocytic 
route. During maturation of MHC class II molecules, they are prevented from binding to endogenous antigens in 
the endoplasmic reticulum by association with the invariant chain (Ii). Invariant chain–MHC class II complexes 
(MHC II–Ii) move through the Golgi to the MIIC/CIIV compartment where the invariant chain is degraded to 
CLIP (class II-associated invariant-chain peptide). CLIP is  removed from the CLIP–MHC class II (MHC–CLIP) 
complexes and exchanged for antigenic peptide. C) Dendritic cells can endocytose antigens released from other 
cells and cross-present them to CD8+ cytotoxic T lymphocytes. The TAP-dependence of such cross-presentation, 
indicates that it involves diversion of the cellular antigens into the conventional MHC class I pathway (Heath et 
al. 2001). 
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Among APCs, DC have the unique ability to load peptides derived from exogenous antigens 
into MHC class I. This process is called cross-presentation.  
The intracellular sites of peptide loading on MHC class I molecules during cross-presentation 
are still unclear (Yewdell et al. 1999; Amigorena 2003). Two main, not-mutually-exclusive 
models have been proposed based on in vitro results (figure 3). The endosomal model predicts 
that after antigen uptake and degradation in endosomes and lysosomes, peptide exchange 
allows loading on internalized MHC class I molecules, which then recycle to the cell surface 
(TAP-independent pathway) (Yewdell et al. 1999). In contrast, the cytosolic pathway model 
proposes that incoming antigens are delivered from endosomes to the cytosol. Once in the 
cytosol, antigens are shunted to the conventional MHC class I antigen–loading endoplasmic 
reticulum pathway dependent on transporter associated with antigen processing (TAP) and 
proteasomes (Yewdell et al. 1999 (figure 4) (figure 3). These two models can be distinguished 
experimentally because the former is sensitive to lysotropic agents (such as NH4Cl) and is 
independent of TAP and proteasomes, whereas the latter is less sensitive to inhibitors of 
lysosomal functions, but is dependent on TAP and proteasomes (Yewdell et al. 1999). 
Depending on the nature of the antigens and of the antigen-presenting cells, cross-presentation 
is either TAP dependent or independent and can be sensitive or resistant to proteasome 
inhibitors at least in vitro (Amigorena 2003). 
Just recently a model for the TAP-dependent MHC class I loading during cross-presentation 
based on the fusion of phagosomes with the endoplasmic reticulum in antigen-presenting cells 
has been suggested (Guermonprez et al. 2003; Houde et al. 2003). This fusion event generates 
a mixed endoplasmic reticulum–phagosome compartment, where peptide loading during 
cross-presentation may occur. The working model from these studies predicts that 
phagocytosed antigens are delivered to the cytosolic face of phagosomes, where they are 
ubiquitinated and degraded by phagosome-associated proteasomes. The resulting peptides are 
then reimported into phagosomes by TAP and loaded onto phagosomal MHC class I 
molecules. Thus, in the cytosolic pathway of cross-presentation, peptide loading would occur 
in mix endoplasmic reticulum–phagosome compartments (Guermonprez et al. 2003; Houde et 
al. 2003). 
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Figure 3: Cross-presentation. The cross-presentation is the process by which peptides originated extracellularly 
(exogenous antigens) can be presented in the context of MHC class I molecules; this is a key feature of DCs.  
 
1.1.5 T cell mediated anti-tumor immune response 
Identification of T cells that recognize tumors in vitro and the identification of tumor antigens 
provided clear indication that the immune system has the potential to recognize and even 
eliminate neoplastic cells. The fact however that tumors develop and grow indicate that 
control of tumor growth by the immune system often fails. 
Several steps are involved in the induction of tumor immunity: 
1) presentation of tumor molecules by DC precursors that involves capture of tumor cells 
and cross-presentation of tumor-associated-antigens (TAAs) by immature DCs 
2) selection and activation of  TAA-specific T cells 
3) homing of TAA-specific effector T-cells to the tumor site and recognition of restriction 
elements leading to elimination of the tumor. 
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1.1.5.1 Tumor-associated-Antigens (TAA) 
TAA may be classified according to their tissue distribution (Renkvist et al. 2001):  
- Ubiquitous antigens  are widely expressed on many normal and neoplastic tissue. Examples 
are carcino-embryonic antigen (CEA) and HER2-neu. 
- Tumor-restricted antigens  are only expressed on neoplastic cells. They can be shared 
among tumors of the same or of different origin and may also be expressed by normal 
spermatocytes and/or spermatogonia of testis (cancer/testis antigens). Examples include 
MAGE antigens, which are a family of related genes (A1-A2-A3-A4-A6-A10-A12), BAGE, 
GAGE, NY-ESO. Tumor-restricted antigens also include unique  antigens, which result from 
point mutations or frame shifts. Example are: CDK-4, MUM-1, MUM-2, b-catenin, HLA-A2-
R170I, ELF2m, myosin-m, caspase-8, KIAA0205, HSP70-2m. Unique antigens derive also 
from fusion proteins (fusion proteins are never found in normal tissues), like bcr-abl  in 
chronic myeloid leukemia, ETV6/AML in acute lymphatic leukemia or Pml/RARa in acute 
myeloid leukemia. 
- Differentiation antigens are expressed in normal and neoplastic cells of the same lineage 
such as melanocytes and melanoma or prostate and prostate carcinoma. Example are antigens 
of the melanocyte lineage, like tyrosinase, MART-1 and gp100, or prostate specific antigen 
(PSA).   
1.1.6  Failure of tumor control by the immune system: tumor immune escape 
mechanisms 
The revival of the immunosurveillance theory came with the knowledge of well-defined and 
structurally characterized tumor-associated antigens (TAAs) and the progress in 
understanding the molecular pathways required for induction and maintenance of an immune 
response. Advances in methodologies to generate TAA-specific cytotoxic T lymphocytes 
(CTLs) and monoclonal antibodies (mAbs) as immunological probes were of critical 
importance for the development of cancer immunotherapies and vaccines. However, contrary 
to the positive results obtained with TAA-specific immunotherapy in animal model systems, 
the clinical response in patients has been disappointing. Frequently, the immune responses do 
not correlate with the clinical responses. Analysising the underlying mechanisms for this 
dichotomy discovered the low immunogenicity of TAAs, lack of immunological markers to 
predict clinical outcomes, and the ability of tumors to escape immune recognition and 
destruction. Those hurdles are currently the challenges for the development and application of 
immunotherapy. 
Introduction 
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Tumors have developed mechanisms to escape immune surveillance already in the priming 
phase by influencing the ability of antigen-presenting cells to adequately prime T cells. In the 
effector phase of an immune response tumor cells block recognition by effector cells of the 
innate immune system (macrophages, complement and /or natural killer cells) and of the 
adaptive immune system (CD8+T cells and B cells) and divert effector cells by affecting T 
cell activity. 
Known mechanisms are the loss or down-regulation of HLA class I antigens, the loss of 
tumor antigens and immunodominance. Loss of surface antigen expression can occur 
independently of the dysregulation of HLA class I expression. The phenomenon of 
immunodominance is the preferential immunodetection of only one or a few epitopes among 
many expressed on a given target (Khong et al. 2002).  
Defect in death receptor signalling, like Fas ligand (FasL) and TRAIL play a role in immune 
surveillance against tumor. Defective death receptor signaling is a mechanism that may 
contribute to the survival and proliferation of tumor cells. Lack of costimulation is also a very 
well known immune escape mechanism: lack of expression of costimulatory molecules by 
tumor cells may lead to T cell anergy and suboptimal activation of NK cells. Activation or 
inhibition of T cells also depends on the presence or absence of cytokines in their immediate 
microenvironment. Tumor cells produce a variety of immunosuppressive cytokines (VEGF, 
IL-10, TGF-b) and chemokines that can negatively effect maturation and function of immune 
cells. In vitro studies show that VEGF inhibits DC differentiation and maturation. IL-10 can 
exert an inhibitory effect on DC differentiation from stem cell precursors. In addition, 
maturation and the functional status of DCs are also compromised by IL-10. This cytokine 
also inhibits antigen presentation, IL-12 production and induction of T helper type 1 
responses in vivo. TGF-b  inhibits the activation, proliferation and activity of lymphocytes in 
vivo.  
Finally, the tumor can induce apoptosis of activated T cells, via FasL-mediated T cell death 
(Khong et al. 2002). 
An immunotherapeutic strategy may be optimal if it achieves three things concurrently: 
provision of appropriate immune activating signals, elimination of inhibitory factors and 
avoidance of the emergence of immunoresistant phenotypes. The latter might be achieved 
when different modalities are combined to sustain a response long enough to complete tumor 
destruction (Khong et al. 2002). 
Many strategies have been developed to overcome these diverse escape mechanisms. More 
recently interest arose from the observation that stress condition may induce a specific 
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immune response against the tumor. These studies started more than twenty years ago, when 
Srivastava discovered that HSPs isolated from tumor were able to induce an immune response 
in mice that protected them from subsequent tumor chanllenges (see session heat shock 
proteins).  
The goal of this study was to investigate whether and when heat shock proteins expressed 
from the tumor, either constitutively or induced upon stress, are appropriate activating signals 
for an antitumor immune response and whether a stress- like heat-treatment affects the 
immunophenotype of a given tumor.  
1.2 EFFECTS OF HYPERTHERMIA ON TUMOR ANTIGENICITY AND 
SUSCEPTIBILITY TO IMMUNE EFFECTOR MECHANISMS 
Among the various treatment modalities for cancer, hyperthermia has recently taken a 
position as treatment for several human cancers (Wust et al. 2002). By acting as a chemo- and 
radiosensitizer and by increasing the blood flow, loco-regional hyperthermia was found to be 
effective in clinical trials for melanoma (Overgaard et al. 1995) as well as for certain other 
solid tumors (Falk et al. 2001). The initial rationale for the use of hyperthermia was based on 
the observation that temperatures above 43°C are directly cytotoxic to tumor cells as a 
function of time. However, the heterogeneous temperature distribution achieved at the tumor 
site ranges between 40°C and 44°C and is frequently below 43°C (Hildebrandt et al. 2002). 
Furthermore, fever- like whole body hyperthermia which ranges between 39°C and 40°C 
shows also efficacy in mouse tumor models and is currently being investigated in phase I 
clinical trials (Kraybill et al. 2002). These studies indicate that the biological effects of 
hyperthermia is most likely not only the result of direct cytotoxicity, but might include other 
mechanisms (Wang et al. 2001; Atanackovic et al. 2002). 
Several groups are currently investigating the immunologically relevant changes in tumor cell 
physiology and the susceptibility to immune effector cells after heat shock treatment. Davies 
et al. published the first studies on the effect of hyperthermia on antigen expression, showing 
a heat-related, dose-dependent decrease of melanoma surface antigens by shedding and 
masking of surface antigens (Davies Cde et al. 1985; Davies et al. 1990). Following the heat 
shock response, further studies showed a decrease in the presentation of exogenous antigens 
by MHC class II (Pepin et al. 1996) and an abrogation of co-stimulatory functions in antigen 
presenting cells (Kuperberg et al. 1991).  Some groups showed that heat shock conditions 
reduce the susceptibility of target cells to monocyte cytotoxicity (Jaattela  et al. 1993), to CTL 
attack (Sugawara et al. 1990; Geginat et al. 1993; Jackson et al. 2000) and to the effect of 
cytokines such as tumor necrosis factor (TNF-a) (Gromkowski et al. 1989; Jaattela 1990; 
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Kusher et al. 1990; Jaattela 1995; Van Molle et al. 2002). Another aspect of hyperthermia is 
that it induces the heat- inducible HSP70, which has a role in protection against stress- induced 
apoptosis (Mosser et al. 2000). In general, these results suggest that heat shock induces a state 
of immunological resistance in tumor cells. 
On the other hand, evidence has accumulated that hyperthermia and the associated heat shock 
response increase the immunogenicity of cancer cells (Mise et al. 1990; Wells et al. 2000). 
These changes include induction of MHC class II-restricted presentation of endogenous 
antigens (Michalek et al. 1992) and the enhancement of MHC class I antigen presentation via 
heat shock protein expression (Melcher et al. 1998; Clark et al. 2001; Ito et al. 2001). 
Expression of inducible HSP70 was also found to be associated with increased tumor 
immunogenicity {Menoret, 1995 #45) and with enhanced susceptibility of tumor cells to 
cytotoxic lymphocytes (Multhoff et al. 1997; Dressel et al. 1999; Dressel et al. 2000).  
With regard to these heat-induced immunological effects the results reported sofar are 
inconsistent, claiming heat- induced immunoresistance as well as immune stimulation.  
Infact it is known that tumor cells surviving a stress like heat-treatment acquire survival 
advantage and resistance against subsequent stress (thermotolerance). This transient resistance 
has been associated with the induction of heat shock proteins (HSP), that are known to exert a 
cytoprotective role. Intracellular HSPs are known to confer resistance to apoptosis and 
protection from LPS toxicity (sepsis) and ischemia/reperfusion injury. These characteristics 
may lead to malignant transformation, resistance to treatment and may influence the invasive 
phenotype. The challenge now is to elucidate when and in what way induced intracellular 
HSPs interferes with the immunorecognition of heated tumors. 
1.3 HEAT SHOCK PROTEINS AND THEIR ROLE IN INNATE AND ADAPTIVE 
IMMUNE RESPONSE 
Heat shock proteins (HSPs) were discovered by Ritossa in 1962, who described for the first 
time the heat shock response in the Drosophila salivary gland (Ritossa 1962). In the following 
decades many investigators showed that HSPs are phylogenetically one of the most conserved 
families of proteins found in all organisms, from procaryotes, yeasts and plants, to eucaryotes. 
In their classical function HSPs are molecular chaperones that assist in protein folding and 
protein translocation. They prevent misfolding and aggregation of proteins and facilitate 
refolding of denaturated proteins (Georgopoulos et al. 1993; Bukau et al. 1998). The induced 
synthesis of HSPs is, at the molecular level, the cellular response to a wide range of 
threatening stimuli such as heat shock, heavy metals, oxidative stress, fever, inflammation and 
serum deprivation. HSPs are not only induced by stress, but they are also associated with 
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physiological processes such as cell cycle, cell proliferation and differentiation (Milarski et al. 
1986). HSP expression has been associated with several pathological states, in particular with 
cancer (Fuller et al. 1994); HSPs are associated with oncogenesis, e.g. through interaction 
with p53 and protection of tumor cells from apoptosis (Jolly et al. 2000). In recent years HSPs 
have been proposed as a tool for cancer therapy. They may function as a tumor-associated 
activation structure (e.g. HSP70), if detected on the surface of certain tumor cells, thereby 
activating the response of NK cells (Multhoff et al. 1997) (Multhoff et al. 1995; Multhoff et 
al. 1996; Multhoff et al. 1999); or as antigen-presenting molecules, eliciting a specific 
immune response by T cells through associated peptides in HSP-peptide complexes (HSP-PC) 
(Srivastava et al. 1994; Wells et al. 2000). 
Most recently HSPs have been discovered as ‘danger signals’ to the innate immune system, 
inducing selective chemokines (CC and CXC chemokines) and their receptors, cytokines (IL-
1, IL-8, interferons, TGF-b , TNFa), acute phase proteins, NK cell receptors, and molecules 
upstream and downstream of the Toll signaling pathways (Magor et al. 2001). Connecting the 
innate with the adaptive immune system has been the rationale for HSP-based anti-tumor 
vaccination (Matzinger 1994; Melcher et al. 1998; Srivastava et al. 1998; Singh-Jasuja et al. 
2001). Table 1 gives an overview of immunologically relevant HSPs.  
Table 1: Heat shock proteins with relevant functions in the immune system (Milani et al. 2002).  
HSP 
family 
Localisation Family member  Immunological function Reference 
HSP60 Mitochondria HSP60 (60 kDa 
chaperonin) 
ATP-dependent chaperone function;  
 
‘Danger signal’ to the innate immune 
system 
(Bukau et al. 1998) 
 
(Chen et al.  1999; Breloer  et 
al. 2001) 
HSP70 Cytoplasm 
 
 
 
 
Cytoplasm 
HSC70 
(constitutive) 
 
 
 
 
HSP70  
(inducible) 
 
ATP-dependent chaperone function;  
‘Danger signal’ to the innate immune 
system;  
Cross-presentation of tumour antigens 
as fusion protein 
 
‘Danger signal’ to the innate immune 
system; cytokine-like function; 
Cross-presentation of tumour antigens 
(Bukau et al. 1998) 
(Panjwani et al. 1999) 
(Somersan et al. 2001) 
 (Wang et al. 2001) (Udono 
et al. 2001; Kammerer et al. 
2002) 
 
(Asea et al. 2000; Kuppner 
et al. 2001) 
 
(Udono et al. 1993; Udono 
et al. 1994; Suto et al. 1995; 
Binder et al. 2001; Castelli  
et al. 2001) 
HSP90 Cytoplasm 
 
 
ER Lumen 
HSP90 a/b 
(HSP86/HSP84) 
 
Gp96 (Gp94, 
endoplasmic) 
Steroid hormone receptors 
Refolds and maintains protein in vitro 
 
ATP-independent chaperone function; 
‘Danger signal’ to the innate immune 
system 
Cross-presentation of tumour antigens 
(Georgopoulos et al. 1993) 
 
 
(Singh-Jasuja et al. 2000; 
Zheng et al. 2001) 
(Udono et al. 1994; Suto et 
al. 1995) 
HSP110 Cytoplasm HSP110 
 
Cross-presentation of tumour antigens (Wang et al. 2001) 
Grp170 ER Grp170 Cross-presentation of tumour antigens (Wang et al. 2001) 
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For most HSP families there is at least one family member that exerts an important function in 
the immune response. The functions are diverse, covering ‘danger signal’ (Chen et al. 1999; 
Breloer et al. 2001) and induction of cytokine secretion (Asea et al. 2000; Singh-Jasuja et al. 
2000; Kuppner et al. 2001; Zheng et al. 2001), chaperone function (Panjwani et al. 1999), 
cross-presentation and T cell stimulation (Udono et al. 1993; Udono et al. 1994; Suto et al. 
1995; Binder et al. 2001; Castelli et al. 2001). 
1.3.1 Biochemistry of the  HSP70 family 
Within the HSP70 family two forms can be distinguished: the inducible form HSP70 (also 
named HSP72, according to their molecular weight MW= 72 kDa) and the constitutive 
isoform HSC70 (also HSP73, MW= 73 kDa). The members of the HSP70 family are 
molecular chaperones which transiently bind and stabilize unfolded and partially folded 
proteins. They control correct folding, oligomerization, translocation through membranes or 
disposal of proteins by degradation (Georgopoulos et al. 1993; Bukau et al. 1998). HSP70 
recognize a wide spectrum of heptapeptide segments with a preference for hydrophobic 
residues (leucine oder isoleucine) with its C-terminal domain (figure 4).  
HSP70 is organized in domains (figure 4): peptide recognition is performed by amino acids of 
the C-terminal domain. The N-terminal amino acids encode the ATPase domain, which is 
important for peptide binding and release. In its ATP-bound state, HSP70 binds and releases 
peptide rapidly, whereas after hydrolysis, in the ADP-state, bound peptide is held tightly 
(Flynn et al. 1989). If HSPs have to be isolated as complex with associated peptides, it is 
essential to use a method which avoids ATP hydrolysis (see methods). 
                 
              
Figure 4: Domain structure of HSP70. HSP70 consists of a phylogenetically conserved NH2-terminal 
nucleotide-binding domain of 44 kD and a less conserved COOH-terminal domain, that binds peptide or 
polypeptide substrate. (Institute of biochemistry Zurich: seminars (www.biochem.unizh.ch/seminars/) 
1.3.2 Receptors and signal mediators for heat shock proteins  
In the last few years effords were directed toward the identification of receptors and 
mechanisms involved in the HSP-mediated activation of the innate and adaptive immune 
system. In 2000, CD91 was identified as a receptor for the HSP gp96. Later  Basu et al. 
N C~ 44 kDa ~ 18 kDa ~ 10 kDa
ATPase domain Peptide binding 
domain
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proposed that CD91 might be a universal receptor for HSP70, HSP90, gp96 and calreticulin 
(Basu et al. 2001). Meanwhile other receptors have been identified, like CD40 and LOX-1, 
which may be involved in the HSP-mediated cross-presentation of antigens (Becker et al. 
2002; Delneste et al. 2002). 
Recently it has been shown that Toll- like receptors (TLR) are involved in the activation and 
maturation of dendritic cells by HSPs (Vabulas et al. 2002). Toll- like receptor proteins are 
important mediators/signal-transducers of the innate immune response to infection (Pugin et 
al. 1994; Medzhitov et al. 1997; Kir schning et al. 1998; Poltorak et al. 1998; Akira et al. 
2000) and are involved in recognizing pathogen associated molecular patterns (PAMPs), like 
LPS. In an attempt to define the mechanistic events for the induction of pro-inflammatory 
responses by HSP it was noted that the response elicited by the different HSPs was similar to 
that of lipopolysaccharide (LPS) (Kol et al. 1999). The binding of LPS to TLR4 results in the 
recruitment of the adaptor molecule MyD88, IL-1 receptor associated kinases (IRAK) and the 
adaptor molecule TRAF6 ultimately leading to the production of pro-inflammatory cytokines 
(Medzhitov et al. 1997; Akira et al. 2001). 
HSP60 (Vabulas et al. 2001), gp96 (Vabulas et al. 2002) and HSP70 (Asea et al. 2002; 
Vabulas et al. 2002) were found to bind to TLR4 and induce a cascade of events similar to 
that of LPS, leading to the secretion of inflammatory cytokines and maturations signals 
(figure 5). 
Thus HSP appear to use these same highly conserved signal transduction pathways and 
receptors, which organisms have used for millions of years to recognize and attack pathogens. 
 
MyD88
IRAKTRAF6
MAPK­
TIR
HSP70
TLR 2/
TLR 4
MD-2
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cytosol
NFkB­
proinflammatory 
cytokines­
TNFa, IL-1, IL-6 
and others
NFkB
IkB
nucleus TLR 2/
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TIR
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MD-2
Internalization
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?
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Figure 5: HSP70 delivers signals through TLR2 and TLR4 in 293T cells . Ligand activation of TLR results in 
the recruitment of the adaptor molecule MyD88, IRAK and the adaptor molecule TRAF6, ultimately leading to 
the production of pro-inflammatory cytokines. How CD91 integrates into this pathway is currently unknown  
(Milani et al. 2002).  
1.3.3 Heat shock protein-peptide complexes (HSP-PC): a tool for immunization  
In murine systems vaccination with heat shock proteins (HSPs) such as glucose regulated 
protein (gp) 96, HSP70, and HSP90 isolated from cancer tissue but not from normal tissue, 
induces specific immunity and cytotoxic T lymphocyte (CTL) activation (Srivastava et al. 
1994). The specificity of the induced CTLs relies on the peptides chaperoned by these HSPs 
(Srivastava et al. 1994) (Suto et al. 1995). This property allows CTL activation without the 
need to characterize the corresponding antigens, and provides the basis for a new type of 
vaccine against cancer (Tamura et al. 1997; Janetzki et al. 2000; Srivastava 2000; Srivastava 
2002). 
Immunization with HSP-peptide complexes (HSP-PC) is exquisitely dependent on the 
presence of functional antigen presenting cells (APCs) in the immunized host, since depletion 
of such cells renders the host incapable of mounting immune responses after injection of 
HSP-PC preparations (Udono et al. 1994). Dendritic cells (DCs) are very effective activators 
of CTLs, a process that requires the presentation of antigen bound to MHC molecules, 
together with expression of adhesion and costimulatory molecules (Banchereau et al. 2000). 
In particular the ability to present exogenous antigens through "cross-presentation“ is a key 
feature of DCs. It became evident that gp96- and HSP70-chaperoned peptides can be 
presented to CTLs by DCs in the context of MHC class I molecules and uptake of gp96 or 
HSP70 requires receptor-mediated endocytosis (Suto et al. 1995) (Arnold-Schild et al. 1999; 
Singh-Jasuja et al. 2000). The mechanisms involved in the stimulation of T cell responses via 
HSP70 and gp96 were studied in murine systems using induced tumors and model antigens 
(Srivastava et al. 1986) (Udono et al. 1993; Udono  et al. 1994) ovalbumin (Breloer et al. 
1998) and viral antigens (Blachere et al. 1997; Ciupitu et al. 1998). More recently, 
immunization with tumor-derived HSPs has also been demonstrated for spontaneous tumors 
(Vanaja et al. 2000). These analyses provided the principle knowledge of HSP-mediated 
cross-presentation and the involvement of antigen presenting cells and have been the basis for 
the first clinical trials involving tumor-derived gp96 (Tamura et al. 1997; Janetzki et al. 
2000).  
 2 GOAL OF THE STUDY 
Goal of the study 
 25 
Since malignant cells are reliably more sens itive to heat than normal cells, raising the 
temperature of the tumor is one way to selectively destroy cancer cells. Upon necrosis tumor 
cells release HSP in the extracellular milieu where they acquire immunostimulatory properties 
and are able to mount an efficient immune response directed against the tumor from which 
they derive. However not every cell dies upon heat treatment and those which survive acquire 
a survival advantage. In fact cytoprotection has been correlated with expression of 
intracellular heat shock proteins, whose induction is the main event of the heat shock 
response.  
To understand the function of the tumor heat shock proteins expressed under physiological 
and stress conditions and to dissect their role in tumor immune recognition as a function of 
intra- versus extracellular location was the goal of this study.  
In particular it was the goal of this study to achieve a comprehensive and integrated view of a) 
the in vitro immunological properties of heat shock protein 70 family members, either 
constitutively produced by tumor cells or induced upon heat shock; b) the interrelation of heat 
shock induced changes in tumor physiology and immune competence, as defined by tumor 
cell sensitivity to immune effector cells.  
 
2.1 THE MODEL SYSTEM  
I selected the human melanoma system because it is well characterized with regards to tumor-
associated antigens, like tyrosinase and Melan-A/MART-1, their epitopes and restriction 
elements for MHC class I and II presentation, and tumor lines with defined antigen expression 
as well as T cells that recognize specific epitopes are readily available. 
2.1.1 The human melanoma model 
Cutaneous melanoma expresses several immunogenic melanoma-associated differentiation 
antigens (Renkvist et al. 2001), whose peptides are recognized by tumor-reactive T cells of 
melanoma patients (Kawakami et al. 2000) which appear to be involved in tumor regression 
and autoimmune vitiligo (Ogg et al. 1998). Their level of expression has been correlated with 
CTL recognition (Rivoltini et al. 1995) (Cormier et al. 1999; Riker et al. 2000) and 
favourable disease outcome (Takeuchi et al. 2003). Table 2 lists some melanoma 
differentiation antigens, their epitopes and the HLA class I restriction elements (Renkvist et 
al. 2001). 
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Table 2: Melanoma-associated differentiation antigens 
 
Antigene       HLA-restriction  Epitope   
   element 
  
Melan-A/MART-1*            A2   AAGIGILTV    
      A2   EAAGIGILTV    
      A2    ILTVILGVL    
     B45   AEEAAGIGIL   
     B45  AEEAAGIGILT   
 
Gp100          A2   KTWGQYWQV  
      A2   TDQVPFSV    
 
Tyrosinase        A1   KCDICTDEY   
      A1   SSDYVIPIGTY   
      A2   YMDGTMSQV    
      A2   MLLAVLYCL    
    A24   AFLPWHRLF    
    B44   SEIWRDIDF    
 
TRP-1 (or gp75)       A31   MSLQRQFLR    
 
          TRP-2          A2   SVYDFFVWL    
      A2  TLDSQVMSL    
     A31   LLGPGRPYR    
     A33   LLGPGRPYR   
     Cw8   ANDPIFVVL    
 
* Two different groups simultaneously discovered this gene and gave it two different names, MART-1 and 
Melan-A respectively  
 
2.1.2  Melanogenesis and antigenic profile associated with progression of malignant 
melanoma 
Many of the melanocyte lineage-related proteins are involved in the biosynthesis of melanin 
(figure 6), in the maintenance of melanosome ultrastructure and in the melanocytes 
proliferation/cell death (i.e. TRP-1) (del Marmol et al. 1996).  
Melanoma often becomes amelanotic as the malignancy progresses, and thereby loses 
expression of some of these genes. This changes the antigenic profile and increases the 
possibility that such cells will selectively escape immune destruction. It has been shown that 
there is a downward trend in the presence of these antigens as the tumor becomes amelanotic. 
The downregulation of tyrosinase and other melanocyte-specific gene expression is likely to 
be mediated by oncogenes or is due to metabolic changes, like an abnormal acidification, that 
induces an aberrant retention of tyrosinase in the early secretory pathways (ER) and an 
accelerated degradation (Halaban 2002), (Halaban et al. 1997). 
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Figure 6: Melanogenesis. Melanogenesis involves the conversion of tyrosine to dopachrome, catalizised by 
tyrosine-related protein 1 (TRP-1) in a two-step reaction involving the rate limiting enzyme tyrosinase. 
Subsequent conversions are mediated by TRP-2 (defining the brown or black appearance of eumelanin) and 
gp100 (controlling the deposition of dihydroxi indole (DHI) into eumelanin). The role of Melan-A/MART-1 
(melanoma antigen recognized by T cell 1) in melanogenesis has not been defined yet (del Marmol et al. 1996). 
 
 
For this study I have focused on two antigens, tyrosinase and Melan-A/MART-1, expressed 
by the human melanoma cell lines 624.38-MEL and SK-Mel 23. The melanoma cell line 
A375 does not express those antigens and served as a control cell line for most of the 
analyses. 
  
 
 
                            
 
 
 
 
Differentiation antigen  Melanoma 
624.38 Mel 
cell lines 
A375 
 
SK-mel 23 
tyrosinase +++ - +++ 
Melan-A/MART-1 +++ - +++ 
Melanotic no no yes 
Tyrosinase 
Melan-A/MART-1 
TRP-1 TRP-2 
gp100 
melanosome 
 
Tyrosine               DOPA        Dopaquinone         Dopachrome           DHI *  Melanin 
* DHI= dihydroxi indole 
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2.2 DESIGN OF THE STUDY 
I investigated the effects of heat shock treatment and in particular the role of heat shock 
proteins in the cellular anti-tumor immune response (figure 7). The effects of heat exposure 
and of the heat shock proteins was studied at different levels: 
 
1. Endogenous antigen presentation and processing of tumor antigens 
2. Susceptibility of tumor cells to immune effector mechanisms 
3. Cross-presentation of tumor antigens by tumor derived HSP70-PC   
 
a) In the first part of the study I focused specifically on the time-temperature dependent 
effects of heat exposure. Based upon the clinical experience of hyperthermia treatment 
of melanoma, I selected two different thermal doses (41,8°C/120 minutes and 45°C/22 
minutes) that mimic the heterogeneity of the achieved temperature distribution within 
the tumor and determined the time-temperature dependent changes in: a) antigen 
expression (tyrosinase and Melan-A/MART-1) at the protein and mRNA level; b) 
expression of the inducible HSP70 and the constitutive HSC70; c) processing and 
presentation of tyrosinase and MART-1 via MHC class I; d) susceptibility of melanoma 
cell lines to cytotoxic T lymphocytes like CD8+ T cells, LAK and NK cells. 
 
b) In the second part of the study, I characterized the role of members of the HSP70 family 
in the cross-presentation of the human tumor-associated antigen tyrosinase. Most studies 
investigating mechanistic events related to HSP-mediated cross-presentation involved 
highly immunogenic antigens either induced by mutagenesis or overexpressed by 
transfection, a situation that does not reflect most human cancers. Different to those 
studies, I investigated the ability of HSP70 to cross-present a naturally expressed human 
tumor antigen, tyrosinase, that is of low immunigenicity, a situation that more closely 
resembles the patient situation. 
 
 
 
 
 
 
 
Goal of the study 
 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Design of the study.  The human melanoma cell line 624.38-MEL naturally expresses, processes and 
presents tyrosinase and Melan-A/MART-1 in the context of MHC class I molecules and expresses both HSP70 
and HSC70. Therefore it was selected as the model system. The goal of the study was to investigate at 37°C and 
during the heat shock response 1) antigen expression, processing and presentation; 2) the susceptibility of tumor 
cells to cytotoxic lymphocytes; 3) role of tumor-derived HSP70-PC in the cross-presentation of tyrosinase and 
activation of dendritic cells. 
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3.1 CHEMICALS 
* Corrosive; ** Toxic; *** Inflammable 
Acetic acid (Merck, Darmstadt, Germany) * 
Acrylamide/Bisacrylamide 40% (Roth, Karlsruhe, Germany) ** 
Adenosine-diphosphate (ADP) (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany)  
ADP-Agarose (Sigma -Aldrich Chemie GmbH, Taufkirchen, Germany) 
Ammonium peroxidisulfate (APS) (Bio-rad, Munich, Germany) 
Antipain (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Aprotinin (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Bovine serumalbumin (BSA) (Fluka, Buch, CH) 
CHAPS (3-((3-Cholamidopropyl)-dimethylammonio)-1-propanesulphonate) (Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany) ** 
Chymostatin (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Cloridric acid (Neolab, Migge Laborbedarf, Heidelberg, Germany) 
Crystal violet (Merck, Darmstadt, Germany)                 
Ethanol (Merck, Darmstadt, Germany) *** 
FluoroLinkTMCy5 (Amersham Pharmacia Biotech, UK)  
Formaldehyde (FA) (Sigma -Aldrich Chemie GmbH, Taufkirchen, Germany) ** 
Glycerine (Sigma -Aldrich Chemie GmbH, Taufkirchen, Germany) 
Glycine (Merck, Darmstadt, Germany)  
G-sephadex (Amersham Pharmacia Biotech, UK) 
HEPES (N-(2-Hydroxyethyl)piperazine-N´-(2-ethanesulfonic acid)) (Sigma -Aldrich Chemie GmbH, 
Taufkirchen, Germany) 
Hydrogen Peroxide (Pharmingen, BD,San Diego California) 
Leupeptin A (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Liquid nitrogen (Linde, Munich, Germany) 
Magnesiumchlorid (Merck, Darmstadt, Germany)  
2-mercaptoethanol (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) ** 
Methanol (Merck, Darmstadt, Germany) *** 
Natrium Chromate Cr51 (PerkinElmer, Boston, MA) 
Paraformaldehyde (PFA) (Sigma -Aldrich Chemie GmbH, Taufkirchen, Germany) ** 
Pepstatin A (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) **  
Phosphoric acid (Merck, Darmstadt, Germany) *** 
Ponceau S (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Q-sepharose (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Silver Nitrate (Sigma -Aldrich Chemie GmbH, Taufkirchen, Germany) ** 
Skim milk powder (Merck, Darmstadt, Germany) 
Sodium Acid (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) ** 
Sodium Carbonate (Merk, Darmstadt, Germany) 
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Sodium Cloride (Merk, Darmstadt, Germany) 
Sodiuhydrogencarbonate (Merk, Darmstadt, Germany)  
Sodiumhydrogenphosphate (Merck, Darmstadt, Germany)  
Sodium Fluoride (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Sodium Pyrophosphate (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Sodium Thiosulfate Pentahydrate (Merk, Darmstadt, Germany) 
Sodium Vanadate (Sigma -Aldrich Chemie GmbH, Taufkirchen, Germany) 
Sodiumdodecylsulfat (SDS)  (Bio-rad, Munich, Germany) 
Tetramethylbenzidine (TMB) (Pharmingen, BD,San Diego California) 
Tetramethylethylendiamine (TEMED) (Serva, Heidelberg, Germany)  
Trypsin-EDTA (Life Technologies Invitrogen, GIBCO BRL, Kalsruhe, Germany) 
Tris(hydroxymethyl)aminomethane (Tris) (Merck, Darmstadt, Germany)  
Trypan blue (Serva, Heidelberg, Germany) ** 
Tween 20 (Merk, Darmstadt, Germany) 
3.2 KITS 
Annexin V/Propidium Iodide (PI) kit (Alexis, Lausen, Switzerland)      
Bio-rad Protein estimation kit Lowry and Bradford (Bio-rad, Munich, Germany) 
Detection system ECL® (enhanced chemiluminescence) (Amersham Pharmacia, Freiburg, Germany)  
FIX und Perm (Dianova, Hamburg, Germany) 
Mycoplasma detection kit by fluorescent DNA staining (Biochrom, Berlin, Germany) 
OPTEIA TM Set Human IFN-g (OptEIA, Becton Dickinson; Heidelberg, Germany)  
3.3 LABORATORY EQUIPMENT, CONSUMABLES 
Autoradiography film (Valmex, Augsburg, Germany) 
Balance BL310 d=0,01g (Sartorius, Göttingen, Germany) 
Balance Mettler Delta Range PM460 d=0,001 g  (Mettler Toledo, Columbus, OH, USA) 
Blottingchamber (Bio-rad, Munich, Germany) 
Cell culture CO2 incubator (Haereus, Rodenbach, Germany) 
Cell culture laminar flow (Bio Flow Technik, Meckenhein, Germany)            
Centrifuges ROTIXA/P (Hettich, Tuttlingen, Germany) 
Developing machine M35X-OMAT Processor (Kodak AG, Stuttgart, Germany) 
ELISA reader (SLT, Crailsheim, Germany)      
Eppendorf ultracentrifuge 2K15 (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
FACSscan (Beckton Dickison, Mountain View, CA) 
Fast Protein Liquid Chromatography (FPLC) Biologic LP (Bio -rad, Munich, Germany) 
Refrigerator (4°C, -20°C) (Siemens AG, Germany)      
Refrigerator (-80°C)  UF80-450S (Colora Messtechnik GmBH, Lorch, Germany)                   
Gammacell 40 (Atmonic Energy of Canada, Ottowa, Canada) 
Gel electrophoresis systems (Bio-rad, Munich, Germany) 
Heating block BT 130-2 (HLC, Haep Labor Consult, Bovenenden, Germany) 
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Liquid nitrogen tank (Cryoson, Schöllkrippen, Germany) 
Magnetic stirrer (Cenco, Breda, the Netherlands) 
Microscope (Carl Zeiss Jena, Germany) 
Microscope, model LSM510 confocal laser-scanning (Carl Zeiss Jena, Germany) 
Nitrocellulose membranes (Sartorius, Goettingen, Germany) 
pH-meter 766 (VWR International, Ismaning, Germany) 
Rotor Ti 75 (Beckman, Palo Alto, CA) 
Shaker (Edmund Bühler, Tübingen, Germany) 
Spectophotometer Smartspec TM 3000 (Bio-rad, Munich, Germany)  
Topcount NXT (Packard, Bioscence, Meriden, CT) 
Ultracentrifuge L7-65 (Beckman, Palo Alto, CA) 
Ultra-turrax (IKA Werke, Staufen, Germany) 
VECTASHIELD (Vector Laboratories Inc., Burlingame, CA) 
Vortex (Cenco, Breda, the Netherlands) 
Waterbath (HAAKE, Karlsruhe, Germany)  
3.4 CELLS 
3.4.1 Tumor cell lines 
Suspension cells 
Cell type  Description Origin 
K562 human myelogenous leukemia cell line ATCC, Rockville, MD 
Daudi Burkitt lymphoma cell line ATCC, Rockville, MD 
 
Adherent cells 
Cell type  Description Origin 
624.38 Mel  (Rivoltini 
et al. 1995)  
human melanoma cell line; 
tyrosinase positive; 
HLA-A2 positive 
was a kind gift from Dr. 
M.C. Panelli (National 
Institute of Health, 
Bethesda, Maryland, USA) 
SK-Mel 23 human melanoma cell line; 
tyrosinase positive; 
HLA-A2 positive 
was a kind gift from Dr. 
M.C. Panelli (National 
Institute of Health, 
Bethesda, Maryland, USA) 
A375 human melanoma cell line; 
tyrosinase negative; 
HLA-A2 positive 
ATCC, Rockville, MD 
BLM human melanoma cell line; 
tyrosinase negative; 
HLA-A2 positive 
was a kind gift from Dr. Y. 
Vissers (Dept. of Clinical 
Oncology, Leiden 
University Hospital, NL) 
A9 Mouse fibrosarcoma cell line which 
expresses Fas after transfection  
was a kind gift of Dr. 
Engelmann, LMU- Munich 
RCC-26 (Schendel et 
al. 1993)  
renal cell carcinoma cell line; 
HLA-A2 positive 
was established by D.J. 
Schendel from a primary 
renal cell carcinoma  
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3.4.2 Cytotoxic lymphocyte clones 
Cell type  Description Origin 
TyrF8 (Visseren et al. 
1995) 
HLA-A*0201-restricted tyrosinase 
peptide (aa 368-376; YMNGTMSQV) specific 
cytotoxic T cell clone 
was kindly provided by Dr. 
P. Schrier (Dept. of Clinical 
Oncology, Leiden 
University Hospital, NL) 
A42 (Kawakami et al. 
1994; Kawakami et al. 
1994)  
The HLA-A2-restricted Melan-a/MART-1 
peptide  (AAGIGILTV)- specific cytotoxic 
T-cell clone A42  
was kindly provided from 
Dr. M.C. Panelli (National 
Institute of Health, 
Bethesda, Maryland, USA) 
JB4 HLA-A2-resctricted cytotoxic T-cell 
clone 
generated in GSF-IMI 
(E.N.) 
LAK Lymphokine-activated killer  cells were generated from PBMC 
of healthy donors 
(GSF-IMI) 
NKL (Robertson et al. 
1996)  
Human natural killer (NK) leukemia cell 
line 
was kindly provided by Dr. 
C.S. Falk (GSF-Institute of 
Molecular Immunology, 
Munich) 
B-LCL LAZ388 EBV-transformed allogeneic B-LCL Dr. A. Mackensen, 
Department Hematology, 
University Regensburg 
3.4.3 Primary cells (PBMC) 
Samples were obtained from leukapheresis or healthy donors, after having informed and 
obtained consent of the donor. Every donor was tested for HLA-A2 surface expression and 
entered into a database. 
3.5 MATERIALS USED FOR CELL CULTURE 
3.5.1 Cell culture media 
3.5.1.1 Medium for tumor cell lines 
RPMI 1640 (Life Technologies Invitrogen, GIBCO BRL, Kalsruhe, Germany ) 
10% FCS (Fetal calf serum) (Biochrom AG seromed, Berlin, Germany) 
1% NEM (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
1% Penicillin/streptomycin (GIBCO BRL, Kalsruhe, Germany) 
1% L-glutamine (GIBCO BRL, Kalsruhe, Germany) 
3.5.1.2 Medium for CD8+ T cells 
RPMI 1640 (Life Technologies Invitrogen, GIBCO BRL, Kalsruhe, Germany) 
7,5% FCS (fetal calf serum) (Biochrom AG seromed, Berlin, Germany) 
7,5% human serum (mixed from 4 healthy donors) 
2mM L-glutamine (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
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1mM Sodium Pyruvate (Life Technologies Invitrogen, GIBCO BRL, Kalsruhe, Germany) 
50 U/ml rIL-2 (Proleukin, Cetus Corp. Emeryville, CA) 
 
Addition for LAK cells 
1% Phytohemagglutinin (PHA) (Difco Laboratories, Detroit, MI)  
10 ng/ml OKT3 (ATCC, Rockville, MD) 
3.5.1.3 Medium for dendritic cells 
VLE RPMI 1640 medium (Biochrom AG seromed, Berlin, Germany) 
Human serum (mixed from 4 healthy donors) 
Penicillin/streptomycin (GIBCO BRL, Kalsruhe, Germany) 
L-glutamine (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
GM-CSF (Hölzel Diagnostika, Köln, Germany) 
IL-4 (Biomol, Hamburg, Germany) 
TNF-a (Biomol, Hamburg, Germany) 
3.5.1.4   Other reagents for cell culture 
Ficoll/hypaque (PAA, Linz, Austria) 
Phosphate Buffer Saline (PBS) (GIBCO BRL, Kalsruhe, Germany) 
Trypan Blue (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Trypsin-EDTA (Life Technologies Invitrogen, GIBCO BRL, Kalsruhe, Germany) 
3.5.2 Culture vessels and plastic ware  
3.5.2.1 Culture flasks and plates and other plastic material 
96-well flat/round plate (Nunc, Wiesbaden, Germany) 
Centrifuge vials (15-50 ml) (Sarstedt, Nümbrecht, Germany) 
Culture flasks (50-250-600 ml) (Greiner Labortechnik, Frickenhausen, Germany) 
Eppendorf tubes (0,5-1 ml) (Eppendorf, Hamburg, Germany)  
Freezing tubes (Nunc, Wiesbaden, Germany)  
Micropipettes, Pipettes (Gilson, Langenfeld, Germany) 
Parafilm M (American National Can, Greenwich, USA) 
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3.5.3 Solutions and antibodies for flow cytometry 
3.5.3.1 FACS solutions 
PBS, containing 5% FCS 
1% PFA in PBS only when fixing cells. 
3.5.3.2  Antibodies  
 
 
PE= Phycoerythrin; FITC= Fluorescein-Isothyocyanat 
Secondary antibodies PE- or FITC conjugated goat anti-mouse IgG, were purchased by 
DAKO, Glostrop, Denmark. 
Antigen 
Specificity 
Primary antibody secondary  origin 
HSP70 6B3: anti-human HSP70, rat 
monoclonal; 1:100 
anti-rat-FITC GSF-IMI (Noessner 
et al. 2002)6) 
HSC70 SPA815: anti-human HSC70, rat 
monoclonal; 1:1000 
anti-rat-FITC StressGen 
Biotechnologies, 
Victoria, Canada 
Pan MHC-
Class I 
W6/32: anti-human MHC I, 
hybridoma cell supernatant, mouse 
monoclonal; 1:2 
PE-conjugated  
goat anti-mouse IgG 
ATCC HB-95 
(Barnstable  et al. 
1978)7) 
HLA-A2 HB-54: anti-human HLA -A2, 
hybridoma cell supernatant, mouse 
monoclonal 
PE-conjugated  
goat anti-mouse IgG   
ATCC HB-54 
(McMichael et al. 
1980)8) 
Isotype 
IgG1 
MOPC 21 PE-conjugated  
goat anti-mouse IgG   
Immunotech 
(Hamburg, 
Germany). 
Isotype 
IgG2a 
MOPC 141 PE-conjugated  
goat anti-mouse IgG   
Immunotech 
(Hamburg, 
Germany). 
CD14 Anti-human CD14, 
mouse monoclonal 
PE-conjugated  
goat anti-mouse IgG   
Immunotech, 
Hamburg, Germany 
CD40 Anti-human CD40, 
mouse monoclonal 
PE-conjugated  
goat anti-mouse IgG   
Pharmingen, BD, 
San Diego 
California  
CD1a Anti-human CD1a, 
mouse monoclonal 
PE-conjugated  
goat anti-mouse IgG   
Pharmingen, BD, 
San Diego 
California 
CD83 Anti-human CD83, 
mouse monoclonal 
PE-conjugated  
goat anti-mouse IgG   
Immunotech, 
Hamburg, Germany 
CD86 Anti-human CD86, 
mouse monoclonal 
PE-conjugated  
goat anti-mouse IgG   
Pharmingen, BD, 
San Diego 
California 
Apo-1 anti-FAS 
mouse monoclonal 
PE-conjugated  
goat anti-mouse IgG   
was a gift of Dr. H. 
Engelmann (LMU-
Munich) 
ML-957 Antibody that cross-link the Fas 
receptor 
  - was a gift of Dr. H. 
Engelmann (LMU-
Munich) 
ML-958 Antibody that does not cross-link 
the Fas receptor 
  - was a gift of Dr. H. 
Engelmann (LMU-
Munich) 
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3.5.4  Fluorescence labeling kits 
- FluoroLinkTMCy5= cyanine dye; produces an intense signal in the far-red region of the 
spectrum, emission ?= 670 nm  
- FITC: Fluorescein-Isothyocyanate; emission ?= 525 nm 
- Conjugation buffer: carbonate-bicarbonate buffer (0,1 M; pH 9,5)  
- Gel filtration column (Sephadex G-25) or 12-14 kDa dialysis membrane 
3.5.5 Buffer and antibodies for ELISA 
3.5.5.1 Buffers for ELISA 
COATING BUFFER (stored at 4-8°C) 
0,1 M carbonate, pH 9,5 
 
ASSAY DILUENT (stored at 4-8°C) 
PBS + 10% FCS 
 
WASH BUFFER (stored at 4-8°C) 
PBS + 0,05% Tween-20 
 
SUBSTRATE SOLUTION 
Tetramethylbenzidine (TMB) and Hydrogen Peroxide 
 
STOP SOLUTION 
1mM Phosphoric acid  
3.5.5.2 Standard and Antibodies for IFN-g ELISA  
Standard recombinant human IFN-g lyophilized Serial dilution* 
Capture antibody anti-human IFN-g liquid 1:250 
Detection antibody biotinylated anti-human 
IFN-g 
liquid 1:250 
Enzyme reagent avidin-horseradish 
peroxidase conjugate 
liquid 1:250 
 
* Serial dilution of the standard after reconstitution. For every new kit, dilution is performed to obtain 
following final concentration: 0/41,6/83,2/ 166/333/1000 pg/ml 
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3.6 MATERIALS USED FOR BIOCHEMISTRY 
3.6.1 Buffers and antibodies for Western Blot and Silver Stain 
3.6.1.1 Buffers for SDS-Polyacrylamidgelelectrophoresis (PAGE) 
for 2 gels Running gel (10%) Stacking gel (10%) 
Acrylamide  6ml 1,3 
Tris  (pH 8,8)  7,6 ml (pH 6,8)   2,5 ml 
10% SDS 200 µl 100 µl 
APS (10% Ammonium 
Persulfate) 
400 µl 100 µl 
Temed (tetramethyl ethylene 
diamine) 
10 µl 10 µl 
  
SDS-PAGE GEL LOADING DYE (2X) 
0,07 g Tris 
1 g glycerin 
0,5 g SDS 
bromphenolblue  
pH 6,8 in 10 ml H2O 
 
ELECTROPHORESIS BUFFER (10X)  
144 g glycin 
10 g SDS 
30 g Tris 
pH 8,3 in 1000 ml H2O 
3.6.2 Buffers for cell lysis and Western Blot  
 
WHOLE CELL LYSIS BUFFER CHAPS  
2% CHAPS 
50 mM HEPES 
200 mM NaCl 
10 mM Sodium Pyrophosphate 
50 mM Sodium Fluoride 
0.2 mM Sodium Vanadate 
PMSF 10µl/ml 
Pepstatin A, Leupeptin A, Aprotinin, Antipain, chymostatin all at 1µl/ml, freshly added just before cell 
lysis 
pH 7,5 
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PONCEAU SOLUTION (10X)  
30 g trichloroacetic acid (TCA) 
2,0 g ponceau  
in 100 ml H2O 
 
TRANSFER BUFFER,  
3,03 g TRIS 
14,4 g Glycine 
200 ml Methanol 
pH 8,3  
in 1000 ml H2O 
 
WESTERN BLOT STRIPPING SOLUTION  
7 ml 2-Mercaptoethanol 
20 g SDS 
7,56 g Tris 
pH 6,7 in 1000 ml H2O 
 
TRIS-BUFFERED SALINE (TBS) 10X  
12,11 g Tris 
88 g NaCl 
pH 7,4 in 1000 ml H2O 
 
TBST (TBS PLUS TWEEN20) 
500 ml TBS 
200 µl Tween20 
 
BLOCKING BUFFER 
5% nonfat dry milk in TBST 
 
PRIMARY ANTIBODY DILUTION BUFFER 
5% nonfat dry milk in TBST 
 
 
Materials 
 40 
3.6.2.1 Antibodies for Western Blot 
 
 
 
 
 
 
 
 
 
 
 
3.6.2.2 Silver Stain solutions 
FIXING SOLUTION  
20 ml methanol 
30 ml H20 
25 µl 37% formaldehyde 
in 50 ml 
 
THIOSULFATE SOLUTION  
0,2g/l Na2S2O3 in 50 ml 
 
NITRATE SOLUTION  
0,1% silver nitrate in 50 ml 
 
DEVELOPING SOLUTION  
15 g Na2CO3  
2 mg Na2S2O3  
37% formaldehyde (freshly before use) 
in 500 ml 
 
DRYING SOLUTION  
5 ml ethanol 
2 ml glycerol 
in 43 ml H20 
Antigen Primary antibody secondary company 
Tyrosinase C-19: anti-human tyrosinase, 
goat polyclonal, 1:500 
anti-goat HRP 1:3000 Santa Cruz 
Biotechnology, Santa 
Cruz, California, USA 
HSP70 6B3: anti-human HSP70, rat 
monoclonal; 1:100 
anti-rat HRP 1:2000 GSF-IMI (130) 
HSC70 SPA815: anti-human HSC70, 
rat monoclonal; 1:1000 
anti-rat HRP 1:2000 StressGen 
Biotechnologies, 
Victoria, Canada 
Tubulin anti-human b-tubulin; rabbit 
monoclonal, 1:1000 
 
anti-rabbit HRP 1:2000 
 
Santa Cruz 
Biotechnology, Santa 
Cruz, California, USA 
MART-
1/Melan A 
A103: anti-human Melan-
A/MART-1, mouse 
monoclonal, 1:100 
anti-mouse HRP 1:2000 
 
DAKO, Glostrop, 
Denmark 
gp-100 
 
HMB45: anti-human gp100, 
mouse monoclonal, 1:50 
anti-mouse HRP 1:2000 DAKO, Glostrop, 
Denmark 
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3.6.3 Buffers and column materials for purification of HSP70-PC 
3.6.3.1 Buffers for protein purification 
3.6.3.2 Column material for protein purification (Downscale 1:3= D3) 
    HiPrep 26/10 
Desalting column 
ADP-Agarose Q- Sepharose  
Column volume 53 ml 
D3= 53 ml 
5 ml 
D3= 2 ml 
5 ml 
D3= 2 ml 
Matrix Sephadex-G 25 fine Adenosine 5´-diphosphate -
Agarose 
Q-sepharose high 
performance 
Column 
dimension 
2,6 x 10 cm 1x10 cm 1 x 10 cm 
Number  3 (D3= 1) 
 
1 1 
Flow rate 3-5 ml/min  
(4 ml/min; 
Fractionation) 
2 ml 
D3= 0,5 ml/min by loading; 
1 ml/min by eluting 
2 ml 
D3= 1 ml/min 
Company Amersham 
# 175087-01 
Sigma -Aldrich; Taufkirchen, 
Germany; 
 #A4398 
Sigma -Aldrich; 
Taufkirchen, Germany 
# Q-1754 
3.6.3.3 Material for protein concentration 
Concentrations tubes, Membra-spin Macro 15 ml (Membrapure, Bodenheim, Germany) 
Characteristics 
Length of the filter 96 mm x 26 mm 
Maximum Sample volume 15 ml 
Maximum final concentrate volume 50 µl 
Effective filtration area 314 mm2 
Tube capacity 50 ml 
Operating temperature 4°C 
Maximal centrifugal force 6000 g 
Rotor angle 45° 
Step Buffer  Composition 
Sample extraction Buffer A:  
hypotonic lysis  
10 mM NaHCO3 
0,5 mM PMSF 
pH 7,1 
ADP-Affinity chromatography Buffer B 20 mM Tris  
20 mM NaCl 
3 mM MgCl2 
15 mM 2-Mercaptoethanol 
0,5 mM PMSF 
pH 7,5 
Anion-exchange chromatography Buffer C 1 
 
 
 
Buffer C2 
 
 
 
Buffer C3 
20 mM Na2HPO4 
20 mM NaCl 
pH 7,0 
 
20 mM Na2HPO4 
600 mM NaCl 
pH 7,0 
 
1000 mM Na2HPO4 
600 mM NaCl 
pH 7,0 
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3.6.4 Plastic ware  
Centrifuge vials (15-50 ml) (Sarstedt, Nümbrecht, Germany) 
Cuvettes (Ratiolab, Dreeich, Germany)  
Eppendorf cups (0,5-1 ml) (Eppendorf, Hamburg, Germany)  
Freezing tubes (Nunc, Wiesbaden, Germany)  
Immuno Maxi 96-Well-Plates (NUNC, Wiesbaden, Germany) 
Micropipettes, Pipettes (Gilson, Langenfeld, Germany) 
Parafilm M (American National Can, Greenwich, USA) 
3.7 SOFTWARE 
Biorad  Biologic LP (Bio-rad, Munich, Germany) for protein purification 
Cellquest software (Bekton Dickison, Mountain View, CA) 
Endnote 
Microsoft Word, Excel, Powerpoint, Photoshop  
Origin 4.1 program 
Software KS 400 (Carl Zeiss Vision, Germany) 
 4 METHODS 
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4.1 CELL CULTURE METHODS 
4.1.1 Cell culture techniques  
4.1.1.1  Storage of cells 
In order to minimize the cellular injury induced by freezing and thawing procedures 
(intracellular ice crystals and osmotic effects), a cryoprotective agents such as dimethyl 
sulphoxide (DMSO) or glycerol are added. A variable number of suspension cells between 2-
10 x 106 are spun down and resuspended in 500 µl of 10% DMSO solution (DMSO diluted in 
fetal calf serum). Freezing vials are cooled before and every step is performed on ice. While 
short-term preservation of cell lines using mechanical freezers (-80°C) is possible, storage in 
liquid nitrogen (-196°C) or its vapour (-120°C) is much preferred. Rapid thawing of cell 
suspension is essential for optimal recovery. 
4.1.1.2  Cell culture of adherent cells  
Base culture medium for tumor adherent cells (624.38-Mel, A375, SK-Mel 23, BLM, A9, 
RCC-26) was RPMI 1640 supplemented with 10 % FCS, 1% penicillin and streptomycin + 
1% L-glutamine. Melanoma cells were supplemented also with 1% NEM non-essential 
aminoacids. 
Cells growing as monolayers on plastic surfaces are held together and to the substratum by 
mucoproteins and sometimes by collagens; in addition, many cell monolayers require divalent 
cations (Ca2+, Mg2+) for their integrity. Thus for releasing cells from monolayers various 
protease solutions are used, sometimes in association with che lating agent. Therefore Trypsin-
EDTA was used for subculturing of adherent tumor cell line according to the following 
protocoll: when cells were seen to be confluent old medium was washed out, monolayers 
were washed with PBS and incubated with 3 ml of Trypsin-EDTA for 5-10 minutes in the 
incubator. Prolonged exposure to trypsin should be avoided as this damages the cells. To 
inactive trypsin, medium containing serum, which contains a natural trypsin inhibitor, was 
added. The cell suspension was then subcultered in a split ratio of 1:3.  
Cell lines were routinely tested for mycoplasma by fluorescent DNA staining using the 
manufactures directions. Cells were incubated at 37°C in a humidified atmosphere of 5% CO2 
and 95% humidity. 
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4.1.1.3 Cell culture of lymphocytes 
TyrF8 and A42 cells were cultured in 24 well plates using RPMI 1640 medium supplemented 
with 2 mM L-glutamine, 1 mM sodium pyruvate, 7.5% heat- inactivated FCS, 7.5% heat-
inactivated pooled human serum (HS) and 50 U/ml of r-IL-2. CTLs were stimulated biweekly 
with irradiated (10.000 rad, using a 137Cs-source Gammacell 40) IL-2-secreting HLA-
A*0201-positive and tyrosinase- and MART-1/Melan-A-positive melanoma cells, irradiated 
(5.000 rad) pooled allogeneic PBMNC and irradiated (15.000 rad) EBV-transformed 
allogeneic B-LCL (LAZ 388). Fresh medium was given every third day and TyrF8 and A42 
cells were split when wells were confluent. For functional assays measuring antigen-specific 
induction of cytokine secretion or cell-mediated cytotoxicity TyrF8 and A42 were used 
between day 8 and 14 after the last stimulation.  
JB4 is a T cell clone that recognizes HLA-A2 expressing cell lines independent of specific 
peptides and indiscriminative of the HLA-A2 molecular subtypes (HLA-A*0201, A*0205 and 
A*0220). The clone was generated in GSF-Institute for Molecular Immunology (E.N.) by 
limiting dilution cloning of an allogeneic mixed lymphocyte tumor cell culture. Briefly, PBL 
from the healthy donor JB (HLA-A2 negative) were used as responder cells against an in-
house renal cell carcinoma line (RCC-26, HLA-A2 positive). After two rounds of stimulation, 
responding T lymphocytes were cloned at a density of 0.3 cells per well in a 96 well round 
bottom plate using irradiated (10.000 rad) RCC-26 cells and pooled allogeneic PBMC (5.000 
rad) as feeder cells. The specificity of JB4 was determined in cytotoxicity and cytokine 
stimulation assays using various allogeneic HLA-typed cell lines and was found to be HLA-
A2 specific. JB4 was propagated similarly to TyrF8 with the exception that irradia ted RCC-26 
cells were used instead of melanoma cells.  
Lymphokine-activated killer (LAK) cells were generated from PBMC of healthy donors. The 
culture was started in medium containing 15% heat- inactivated FCS, 100 U/ml of 
recombinant IL-2 and one single inducing dose of 1% of phytohemagglutinin and 10ng/ml of 
mAb OKT3. PHA and anti-CD3 were omitted during expansion culture. After 3 to 4 weeks a 
population of activated CD4- and CD8-positive T cells was obtained. The percentage of NK 
cells was less than 2%. Non-MHC-restricted cytotoxicity was confirmed by testing the culture 
against 51Cr-labelled MHC class I negative Daudi cells. The percentage of lysis was routinely 
between 60-75% at an effector to target ratio of 10:1. The human natural killer cell line NKL 
was cultured in medium containing 15% heat- inactivated FCS, and 100 U/ml rIL-2. Cell 
density was adjusted to 0.3x106/ml the day before use. Cytotoxicity against MHC class I 
negative K562 was always more than 30% at an effector to target ratio of 10:1. 
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4.1.1.4  Generation of dendritic cells from monocytic precursors 
The base medium for the generation of dendritic cells was a very low endotoxin (VLE) (< 
0,01 EU/ml) RPMI 1640 supplemented with 1 % human serum, 1% glutamine and 100 U/ml 
penicillin and streptomycin. This special medium was chosen to avoid/reduce the interference 
of endotoxin on the maturation of dendritic cells. Peripheral blood mononuclear cells (PBMC) 
were prepared from leukapheresis samples or from venous blood samples of healthy donors 
by density gradient centrifugation over Ficoll/hypaque. To obtain CD14+ monocytes, 30 x 106 
PBMC were incubated in 75 cm2 plastic flasks for 2 hours in 15 ml base medium and the non-
adherent cells were washed off. The adherent cells were then cultured for 8 days in 15 ml 
dendritic cell base medium, containing GM-CSF (1000 U/ml) and IL-4 (800 U/ml) were. GM-
CSF was added again on day 4 of culture.  
4.1.2 Heat shock treatment  
Heating was performed by directly immersing the cell culture flasks sealed with parafilm in a 
temperature-controlled water bath. Control cells were sealed and incubated at 37°C for 
exactly the same time as the heat-exposed samples. After treatment the cells were returned to 
37°C/5% CO2 and allowed to recover for different time periods (up to 7 days). At defined 
time points of recovery, non-viable cells in the supernatant were washed out and only 
adherent, viable cells were trypsinized and harvested for analysis. 
4.1.3 Clonogenic assay 
The ability of tumor cells to form colonies after various hyperthermia exposures was assessed 
using the clonogenic assay as described previously (Overgaard et al. 1979; Issels  et al. 1990). 
Exponentially growing cultured melanoma cells were exposed to different temperatures 
between 41,8°C and 45°C for different incubation times (10 to 150 minutes).  
At defined time-points viable, adherent cells were harvested by trypsinization and seeded in 
duplicate T25 tissue culture flasks at 100 and 500 cells/flask and allowed to form colonies in 
an undisturbed, humidified, 37°C/5% CO2 air atmosphere. After 7 days, flasks were washed 
with 0,9% NaCl solution and cell colonies were stained with crystal violet solution (20% 
ethanol, 0,8% ammoniumoxalat and 2% cristal violet). Only colonies containing at least 50 
cells were considered to be viable survivors. The number of colonies was counted and colony 
efficiency of each treatment was scored as survival fraction (SF), according to the formula: 
SF= number of colonies for a defined temperature and duration/(number of plated cells x PE). 
PE is the plating efficiency that is determined by dividing the number of colonies of untreated 
cells by the number of plated cells. The mean PE in three independent experiments for the 
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624.38-MEL cell line was 89% (0,89 ± 0,01). The survival fractions were plotted on a 
logarithmic scale (y-axis) against the time of heat exposure (in minutes) on a linear scale (x-
axis). The “breakpoint temperature” was defined as the critical temperature where cells above 
this level start to dye exponentially. The breakpoint temperature for 624.38-MEL cells was 
determined to be 43,5°C. 
4.1.4 Thermal isoeffect doses and cell viability 
Heat exposure as a function of time was performed using temperatures below (41,8 °C) and 
above (45°C) the breakpoint temperature (43,5°C) for 624.38-MEL cells. The duration of heat 
exposure was adjusted to achieve equivalent survival fractions at the specified temperatures 
(thermal isoeffect dose, TID) according to the classical methods (Dewey 1994). In 624.38-
MEL cells isosurvival fractions of 45% were achieved when cells were heated either at 
41,8°C for 120 minutes or at 45°C for 22 minutes.  
4.1.5 Flow cytometry analysis 
Flow cytometry is as a technology to measure properties of cells related to scatter light. In the 
flow cytometer, the light source is a laser. Cells in liquid suspension flow in response to air 
pressure past an objective lens. Filters remove the excitation light to allow the emission light 
to be seen or measured. Most flow cytometers can measure two kinds of light from cells: 
Light scatter and fluorescence (FL). Light scatter is the interaction of light and matter. All 
materials, including cells, will scatter light. The measurements made by the detectors are 
called forward light scatter (FSC), which provides some information on the relative size of 
individual cells and side light scatter (SSC), which provides some information on the relative 
granularity of individual cells. In fluorescence, dye molecules are excited by light of a 
characteristic wavelength (or "color"), which then produce emitted light of a longer 
wavelength. The only light measured originates from the dye molecules. The fluorescent dyes 
that I used were PE (excited by 488 nm argon laser; emission peak at 578 nm; detected in FL-
2), FITC (excited by 488 nm argon laser; emission peak at 519 nm) detected in FL-1)  and 
Cy5 (excited by dye or 633 nm He-NE lasers; emission peak at  670 nm) detected in FL-4 on 
dual laser instruments). The method for staining is described below. 
To consider specific populations of cells within a dot plot a gate is drawn around the desired 
population in the FSC/SSC plot. Live cell were defined according to light scatter properties. 
Usually a total of 10.000 events in the live cell gate were analyzed.   
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4.1.5.1 Surface staining 
For surface immunostaining, cells were incubated with primary antibodies for 30 minutes at 
4°C, washed with PBS + 5% fetal calf serum and then incubated with PE-conjugated goat 
anti-mouse IgG for 30 minutes at 4°C. After washing, cells were analyzed for fluorescence 
staining using a FACScan and Cellquest software.  
To measure overall MHC class I molecule expression, the hybridoma cell supernatant W6/32 
was used in a 1:2 dilution. To detect the HLA-A2 allotype, the hybridoma supernatant HB54 
was used undiluted; the antibody APO-1 recognizing the Fas receptor was used at 10 ng/ml. 
Levels of apoptosis and/or necrosis were tested using the Annexin V/Propidium Iodide (PI) 
kit. To assess DC maturation CD1a, CD40, CD86, CD14 and CD83 antibodies were used.  
4.1.5.2 Intracellular staining 
Intracellular staining for HSP70 and HSC70 was performed using the permeabilization kit 
“Fix and Perm” according to the manufacturer´s instructions. Briefly, cells were washed with 
PBS plus 5% fetal calf serum and permeabilized with reagent A for 15 minutes at room 
temperature. After washing, cells were incubated with reagent B and the primary antibody for 
30 minutes at 4°C in the dark. Cells were washed with PBS plus 5% FCS and then incubated 
with reagent B containing the secondary antibody for 30 minutes at 4°C in the dark. After 
washing, cells were fixed in 1% paraformaldehyde and analyzed for fluorescence staining 
using a FACScan and Cellquest software. Primary antibodies included the monoclonal rat 
IgG1 6B3 recognizing the inducible human HSP70, the monoclonal rat SPA-815 specific for 
the constitutively expressed HSC70. All rat-derived primary antibodies were detected using a 
FITC-conjugated secondary antibody (1:50).  
4.1.6 T cell stimulation assay 
Adherent melanoma cells were harvested, counted and plated in triplicates in 96-well flat 
bottom plates at 10.000 or 5000 cells/well in 100 µl fresh base medium. CD8+ T-cell clones 
were added at ratios of 5:1 or 2,5:1 respectively, i.e 2000/well in 100 µl T cell medium. The 
T-cell clones were TyrF8, recognizing the HLA-A2/Tyr 368-376 (YMNGTMSQV)-peptide 
complex, A42, recognizing the HLA-A2/MART-1 (AAGIGILTV) peptide complex and JB4, 
a CD8+ T-cell clone that recognizes the HLA-A2 protein itself, independently from its bound 
peptide repertoire. Culture supernatants were harvested after 24 hours and the content of IFN-
g  as a surrogate marker for T-cell activation was determined using a commercially available 
ELISA. Background values arising from T-cells or melanoma cells cultured alone were 
generally below 5 pg/ml and were substracted from the experimental values. 
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4.1.7 Cell mediated cytolysis (CML) 
Cell-mediated lysis of 624.38-MEL by MHC-restricted T-cell clones TyrF8, A42 and JB4 and 
non-MHC-restricted lymphocytes, LAK and NKL was quantitated using the standard 4-5h 
51Cr-release assay (Schendel et al. 1979). One milion target cells were incubated with 
radioactive sodium chromate (Na2 51CrO4) for 1,5 hours at 37°C. After the incubation time, in 
which target cells uptake sodium chromate, cells were washed twice with RPMI + 15% FCS 
to remove sodium chromate in the supernatant. Meanwhile effector cells were counted and 
plated in 96-well round bottom plate in a final medium (RPMI/15% FCS) volume of 200 
µl/well. Effector cells were then titrated to obtain effector to target cell ratios ranging from 
10:1 to 1,25:1. Target cells were added to effector cell titrations  at a concentration of 
2000/100 µl/well and coincubated for 4 hours at 37°C. After 4 hours incubation, 50 µl of 
supernatant were collected and the radioactivity was measured by a TopCount NXT 
microplate scintillation and  luminescence counter with TopCount NXT software. Sodium 
chromate in the supernatant is released by the target cells through the effector cells-mediated 
lysis. Spontaneous release was determined by incubating target cells alone and the total 
release was determined by directly counting labeled cells. The percentage of cytotoxicity was 
calculated as follows: % specific lysis = (experimental cpm-spontaneous cpm/ maximal cpm – 
spontaneous cpm) X 100. Duplicate measurements of four-step titration of effector cells were 
used for all experiments. K562 and Daudi cells, which lack MHC class I molecules, were 
used as negative control for the T cell clones and as positive control for LAK and NKL lysis.  
4.1.8 Cross-presentation assay 
In this assay the ability of an antigen-presenting cell to uptake, process and present an 
exogenous antigen in the context of MHC class I molecules to specific CTLs is tested. This 
mechanism is known as cross-presentation and is a key feature of dendritic cells. Pre-requisite 
for this assay is that APC must be viable. I hypothesized that HSP70-PC isolated from the 
tyrosinase-positive 624.38-MEL cell line (see biochemical methods) carry tyrosinase-derived 
peptides and are able to transfer them into the MHC class I presentation pathway of dendritic 
cells (cross-presentation of tyrosinase). In this assay DC from peripheral blood monocytes 
were used as APC. Immature DC were loaded with tumor-derived HSP70-PC and finally 
matured with a “danger signal” to reach the optimal stage to prime and/or activate CD8+ T 
cells. In particular, DCs derived from monocytic precursors were seeded on day 7 at a 
concentration of 104 cells per well in 96-well round bottom plates in 100 µl of DC culture 
medium (see materials) and HSP70-PC were added to obtain final concentration of 1-10-100-
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1000 ng/ml. After 24 hours, DCs were induced to mature by addition of 200 U/ml TNF-a and 
incubated for additional 24 hours. As a control for the T cell stimulation capacity of the DCs 
tyrosinase peptide (aa 368-376; YMNGTMSQV) was added exogenously at concentrations 
ranging from 1 to 10 µg/ml to TNF-a-matured DCs two hours prior to addition of T-cells. 
TyrF8 cells were added (2 x 104 cells/well) in 100 µl of medium to give final concentrations 
of 25 U/ml IL-2, 5% FCS and 5% HS. After 24 hours, culture supernatants were harvested 
and the content of IFN-g was measured by OptEIA. To rule out the possible influence of 
contaminating LPS, which influences the maturation of DC being itself a “danger signal”, 
polymyxin B was added at a concentration of 1 µg/ml together with HSP70-PC. To confirm 
that the cross-presentation of tyrosinase-derived peptides was HLA-A2 restricted, antibody-
blocking experiments were performed. Before adding the T-cells, DCs were incubated for 1 
hour at 37°C with the mAb HB54 (20 µg/ml), which binds specifically to HLA-A2 molecule 
(see material). Moreover, to prove that the mechanism of cross-presentation can only be done 
by viable cells, DC were fixed with paraformaldehyde. Fixed cells are not able to uptake or 
process antigens, but they express MHC molecules on their cell surface and are able to bind 
exogenously added peptides. Immature DCs were fixed with paraformaldehyde (1%) for 10 
min at room temperature, then they were washed three times with excess of VLE-medium 
before being used in cross-presentation assays.  
4.1.9 ELISA 
Measurement of IFN-g was used to detect the activation of T cell clones, when incubated with 
DC or with melanoma cell lines. 
Immuno Maxi 96-Well-Plates were coated with 100 µl/well of capture antibody diluted in 
coating buffer. The plates were sealed and incubated at 4°C over night. Wells were aspirated 
and washed three times with 400 µl/well wash buffer. The plates were blocked with 100 µl 
blocking buffer, sealed and incubated at room temperature for 1 hour. Wells were aspirated 
and washed three times with 400 µl/well wash buffer. 45 µl of the samples and the standard 
were pipetted in the wells, sealed and incubated at room temperature for 2 hour. Wash step 
was repeated for 5 times. Detection and avidin-horseradish peroxidase conjugate (HRP) 
antibodies diluted in assay diluent were given at 100 µl/well. Plates were sealed and incubated 
at room temperature for 1 hour. Wash step was repeated for 7 times. Substrate solution was 
added at 100 µl/well, plates were not sealed and incubated for 30 minutes in the dark. Stop 
solution was added at 50 µl to each well. Absorbance was finally read within 30 minutes at 
450 nm by a standard ELISA-reader. 
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4.1.10 Confocal microscopy 
Immature DCs were incubated with 5 µg Cy5-labeled HSP70-PC or Cy5-labeled BSA for 30 
min at 4°C (surface staining) or at 37°C (uptake studies). After washing, cells were settled on 
poly-L-lysine coated glass slides, fixed with 4% paraformaldehyde in PBS for 30 min at room 
temperature and mounted with VECTASHIELD. Samples were analyzed for transmission and 
fluorescence using a Zeiss model LSM510 confocal la ser-scanning microscope equipped with 
an external Helium-Neon Laser 633 nm), lens CAPO 63x/1.2 W as well as equipment for 
digital interference contrast (DIC). Confocal section of specific fluorescence and DIC contrast 
image were taken simultaneously. Fluorescence of the Cy5- labeled probe was detected using 
an excitation wavelength of 633 nm, and a 650 nm LP emission filter. DIC Images were 
treated by multiplicative shading correction using software KS 400. 
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4.2 BIOCHEMICAL METHODS 
4.2.1 Fluorescence labeling of proteins (Cy5) 
Purified HSP70-PC (from A375-MEL melanoma cells) or BSA (1 mg/ml) was incubated with 
FITC (50 µg) or FluoroLinkTMCy5 in carbonate-bicarbonate buffer overnight at 4°C, or 5 h at 
room temperature for Cy5. Free unconjugated FITC was removed by passing the mixture over 
a gel filtration column (Sephadex G-25). For Cy5- labeling, protein was dialyzed (12-14 kDa 
dialysis membrane) for 12-14 h. FITC-conjugated proteins were analyzed by SDS-PAGE and 
immunoblotting using anti-HSP70 mAb and anti-FITC Ab. Labeled proteins were centrifuged 
at 100.000 x g before use to remove any particulate matter. 
4.2.2 Biochemical analysis of protein expression 
4.2.2.1 Cell lysis 
Melanoma cells were lysed in 3-((3-cholamidopropyl)dimethylammonio)-1propanesulfonate 
(CHAPS) buffer for 30 minutes at 4°C.  
4.2.2.2  SDS-Polyacrylamidgelelectrophoresis (PAGE) 
To separate proteins according to their molecular weight, whole cell lysates containing 40 µg 
protein as determined by the Lowry method (see estimation of protein concentration) were 
first denatured by boiling at 95°C for 5 min in SDS gel loading dye (see material), loaded into 
a lane of an horizontal 10% SDS-PAGE gel and electrophoretically separated at 150 volts in 
running buffer. A marker with well-characterized proteins allows to identify the molecular 
weight of unknown proteins. Gel must be freshly prepared.  
4.2.2.3 Western Blot analysis 
After electrophoresis, proteins can be transferred to nitrocellulose membranes in blotting 
buffer for 1 hour at 75 volts and probed with appropriate Ab.  
To visualize proteins on the membrane, the membrane can be stained with Ponceau staining, 
which binds every protein. To detect specific proteins, selected antibodies were used. Before 
incubating with appropriate Ab, the membrane has to be blocked in 5% dry-milk in PBST for 
at least 1 hour, in order to block nonspecific binding sites. The membrane is incubated with 
the primary antibody diluted in 5% milk solution for variable times: 1 hours at room 
temperature for HSP70 and HSC70, over night at 4°C for tyrosinase or Melan-A/MART-1. 
The membrane is washed 3 times for 15 minutes in TBST and then incubated for 1 hour at 
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room temperature in horseradisch peroxidase (HRP)-conjugated antibody diluted in 5% milk 
solution. The membrane is washed 3 times for 15 minutes. Detection of protein/antibody 
complexes is achieved by the ECL (Enhanced Luminol Reagent) system. This western blot 
chemiluminescence reagent is a non-radioactive light emitting system which detect the 
complex protein/antibody immobilized on a membrane by the oxidation of luminol, which 
results in light emission at a wavelength of 428 nm, captured by an autoradiography film. 
4.2.2.4 Silver staining of proteins separated by SDS-PAGE gels 
The protocol was from Bloom (Bloom et al. 1987). After electrophoresis, the gel is fixed for 
10 minutes in 50 ml formaldehyde fixing solution; then washed twice in water for 5 minutes 
and soaked for 1 minute in 50 ml thiosulfate solution by agitating slowly. Then, the gel is 
washed for 20 seconds with water and soaked for 10 minutes in 50 ml of nitrate solution. 
After washing with water, the gel is soaked in 50 ml thiosulfate developing solution until 
band intensities reach the desired intensity (about 1 minute); after washing with water for 10 
minutes, the gel is fixed in 50 ml drying solution. Gels are dried over night at room 
temperature between two pieces of wet dialysis membrane, clamped on the edges of special 
frames.  
4.2.2.5  Estimation of protein concentration 
To estimate the protein concentration of a sample different assays were used: the Bradford 
(Bradford 1976) and Lowry (Lowry et al. 1951) assay are colorimetric assays. The Lowry 
assay is based on the reaction of protein with an alkaline copper tartrate (reagent A) solution 
and Folin reagent (reagent B), which leads to a blue reaction with maximum absorbance at 
750 nm and minimum at 405 nm. Proteins are measured at 750 nm. The Lowry method is a 
widely used method with high sensitivity (2-100 µg), but with a significant chemical 
interference (incompatible with ß-mercaptoethanol). The Bradford assay has few chemical 
interferences, is more sensitive (1-20 µg) and rapid. Proteins are measured at 595 nm. 
 
 
4.2.3 Purification of HSP70-PC 
4.2.3.1 Introduction to the purification of proteins 
Proteins are purified using chromatographic purification techniques, which separate  
according to different properties: charge, biorecognition and size.  
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Protein property Technique Features Sample end condition Column matrix 
for HSP70-PC 
Charge ion exchange 
(IEX) 
high resolution, 
capacity and 
speed  
high ionic strength, 
CONCENTRATED 
Q-sepharose 
Biorecognition affinity  
(AC) 
high resolution, 
capacity and 
speed 
elution condition, 
CONCENTRATED 
ADP-Agarose  
Size gel filtration 
(GF) 
good resolution buffer exchanged;  
DILUTED 
G-Sephadex 25 
 
Before starting the purification it is important to define the properties of target proteins in 
order to check the “stability window”, especially concerning pH and ionic strength, to avoid 
irreversible inactivation. General rules are to work rapidly at low temperature to maintain 
temperature stability, select the right buffers for extraction and purification and the condition 
for ion exchange to maintain pH stability; and add inhibitors to block protease activity. 
4.2.3.2  The ”3-Phase Purification” strategy 
The basic scenario for protein purification is best described by a ”3-Phase Purification 
strategy”: capture, intermediate purification and polishing. 
1) Capture : The goal is to isolate, concentrate and stabilize the target product. The 
technique used is affinity chromatography. Affinity chromatography separates proteins 
on the basis of a reversible interaction between a protein and a specific ligand attached 
to a chromatographic matrix. It offers high selectivity, high resolution, and high 
capacity for the protein of interest. Our target protein, HSP70-PC is specifically and 
reversibly bound to a complementary binding substance (ADP-Agarose). The sample 
is applied under conditions that favor specific binding to the ligand. Unbound material 
is washed away (not ADP binding proteins) and the bound target protein (HSP70-PC) 
is eluted by using a specific competitive ligand (ADP).  
2) Intermediate purification: the goal is to remove most of the bulk impurities (other 
proteins, nucleic acids, endotoxins). The technique used is ion exchange 
chromatography. Ion exchange chromatography separates proteins according to 
charge. It has a very high-resolution with high sample loading capacity. The 
separation is based on the reversible interaction of a charged protein with an 
oppositely charged chromatographic medium. Proteins bind as they are loaded onto a 
column. After binding, proteins are eluted differentially by using either stepwise or a 
continuous salt (NaCl) gradient. For the purification of HSP70-PC, proteins were 
eluted using a gradient from 20 to 600 mM NaCl. The net surface charge of proteins 
varies according to the surrounding pH. When above its isoelectric point (pI) a protein 
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will bind to an anion exchanger, when below to a cation exchanger. The pI of HSP70 
is below pH 7,0 (pI= 5,37-5,48), therefore a strong anion exchanger (Q) has to be 
used. 
3) Polishing : the goal is to achieve high purity by removing any remaining trace 
impurities or closely related substances. The technique used is gel filtration, which 
separates proteins according to the molecular size. This is ideal for final polishing 
steps in a purification in which the sample complexity has been reduced. 
4.2.3.3 Column packing, equilibrating and storage 
Before use, all columns have to be equilibrated with appropriate buffer in order to remove 
storage buffer or, for flow gradients, to bring the column material at the working 
concentrations of ions and pH. To equilibrate a column, at least two-column-volumes (2 CV) 
of buffer have to be run through the column. For anion exchange chromatography, the 
equilibration is done using a high salt continuous gradient between 20 mM and 1000 mM 
NaCl. After use, columns are stored in 20% ethanol at 4°C. 
4.2.3.4  Source of material for HSP70-PC purification 
The sources for HSP70-PC were cell-pellets from the tyrosinase-positive human melanoma 
cell lines 624.38-MEL, SK-MEL 23 and the tyrosinase-negative human melanoma cell line 
A375. Cells were harvested by centrifugation, were resuspended in few µl of PBS and frozen 
at –80°C. The size of the cell-pellet for one isolation was between 5 to 10 ml. For the 
downscale method (1:3) D3, the cell-pellet was reduced to 1/3. Cell-pellets of appropriate 
volume were thawed, resuspended and re-frozen in buffer A (hypotonic lysis containing anti-
protease PMSF).  
4.2.3.5  Cell lysis, centrifugation and ultracentrifugation 
The goal of this step is to solubilize the cellular proteins, to remove the particulate matter like 
cell membrane fragments or organelles and clarify the sample before loading the 
chromatographic columns. 10 ml cell pellet of 624.38-MEL, A375 or SK-Mel 23 were lysed 
in hypotonic buffer by 3 cycles of freeze/thaw, followed by homogenization using Ultra-
turrax about 2 minutes. The cellular homogenate was centrifuged for 5 minutes at 3000 rpm. 
Homogenization and centrifugation of the cell pellet was repeated twice. Before loading the 
first chromatography column, ultracentrifugation was performed to remove lipids and 
particulate matter (50.000 x g for 50 minutes at 4°C; Rotor Ti75). 
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4.2.3.6  Gel filtration  
In order to remove small molecules and salts and to exchange the sample buffer from the 
hypotonic buffer into the appropriate buffer for affinity chromatography (buffer B: 20 mM 
Tris-acetate, 20 mM NaCl, 15 mM 2-ME, 3 mM MgCl2, 0,5 mM PMSF, pH 7,5) after sample 
extraction, Sephadex G-25 gel filtration was used. In the following figure a profile example of 
a gel filtration is shown. Proteins are detected at 280 nm (left axis, absorbance) and salts 
interfere with the conductivity (right axis, msiemens/cm). Higher molecular weight molecules 
are eluted first.  
Figure 8 
 
Figure 8: Example of diagram of a gel filtration (Biologic LP Software). For explanation see 
text.  
4.2.3.7  ADP-Affinity chromatography 
The sample eluted from the Sephadex G-25 was applied directly to an ADP-agarose column 
equilibrated with buffer B. HSP70-PC bind to ADP-agarose, while non-ADP binding proteins 
are immediately eluted. The column was washed extensively with buffer B until no more 
protein was detectable in the eluate by measuring the absorbance at 280 nm. To eluate ADP-
binding proteins, the column was incubated with buffer B containing 3 mM ADP at room 
Gel filtration; G-sephadex 25
mS/cm
OD
280 nm
Time [minutes]
0    5    10    15       20 25  30
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temperature for 30 min and subsequently eluted with the same buffer. If the volume of the 
sample loaded is too high, the binding sites of ADP-agarose may be saturated and some ADP-
binding proteins may be eluted together with the non-ADP-binding proteins. Therefore the 
eluted non-ADP binding protein fractions may be reloaded on the ADP-agarose. In the 
following figure an example of two consecutive ADP-affinity chromatography is shown. 2’ 
and 2’’ represents the first and second elution of non-ADP binding proteins, respectively. 
3’and 3’’ are the first and second elution of ADP-binding proteins, respectively, which can be 
eluted only after adding the competitive agent ADP.   
 
Figure 9 
Figure 9: Example of diagram of a ADP-affinity chromatography (Biologic LP Software). 
For explanation see text.  
 
4.2.3.8  Ion exchange chromatography 
To separate the HSP70-PC from other ADP-binding proteins, ion exchange chromatography 
followed. ADP-binding proteins eluted from the ADP-agarose column were loaded into a 
Mono-Q-Sepharose and eluted over a 20-600 mM NaCl gradient (figure 10). The fractions 
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59-69 were pooled and analzed by SDS-page and western blot (Figure 10). The fractions 
containing HSP70 had less contaminating proteins, as determined by SDS-PAGE silver stain 
and by dot blot with anti-HSP70 mAb (figure 11, lane 7), than before Mono-Q-Sepharose 
(figure 11, lane 6). 
Figure 10 
Figure 10: Example of diagram of an anion-exchange-chromatography (Biologic LP 
Software). For explanation see text. Fractions 59-69 were pooled. 
4.2.3.9  Gel filtration 
The pre-packed column PD-10 containing G-Sephadex 25 was selected for gel filtration: on a 
PD-10 column 2,5 ml of sample was loaded. Elution followed with sterile PBS. The first 3 ml 
contain the proteins; the following 10 ml contain salts. In this way, salts from the Mono-Q 
Sepharose column were removed and the buffer exchanged to PBS. 
4.2.3.10  Sample concentration  
During gel filtration the sample volume increased. Therefore, to achieve high protein 
concentration, samples were loaded into a membra-spin Macro concentration tube. To avoid 
undesiderable binding of proteins to the membrane filter, tubes were pre- incubated for 2 hours 
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with PBS + 5% Tween-20 solution. These tubes were then washed with PBS and filled with 
3,5 ml of the sample and spun at 3000 rpm in a cooled centrifuge (4°C) for 30-60 minutes. 
The concentrated protein was filtered through a 2 µm filter to remove any possible bacterial 
contamination, aliquoted and stored at – 80°C. 
 
4.2.3.11  Flow-chart of HSP70-PC purification (Noessner et al. 2002)  
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4.2.3.12  Final protein characterization through the steps of the HSP70-PC purification from 
melanoma lines 
 
Figure 11 
 
 
Figure 11 shows a silver stained gel and the western blot for HSP70/HSC70 of the single 
steps of the isolation of HSP70-PC. By silver staining the purity of a purified protein can be 
assessed (presence of not desired proteins) and in western blot its identity. Aliquots from each 
purification step were resolved by SDS-PAGE (10%) and silver stained or transferred to a 
membrane for western blot. Lane 1: Cell lysate after buffer exchange through Sephadex G-25; 
lane 2: run through the first ADP-Affinity chromatography, containing non-ADP binding 
proteins; lane 3: eluate from the first ADP Affinity chromatography containing ADP-agarose 
bound protein; lane 4: run through the second ADP-Affinity chromatography; lane 5: eluate 
from the second ADP Affinity chromatography; lane 6: ADP-binding proteins buffer 
exchange through Sephadex G-25; lane 7: Anion-exchange chromatography through mono-Q 
Sepharose: Pool of the pure fractions; lane 8: endproduct: HSP70-PC in PBS. A 
contaminating protein of molecular weight of about 60 kDa was detected in this experiment. 
Sequencing analysis in collaboration with Dr. Kähne, “Immunology research center”, 
University of Magdeburg, revealed that this protein was keratin. This was not reproducible. 
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4.3 STATISTICAL ANALYSIS 
The statistical significance of experimental values was assessed by means of Student’s t-test. 
The t-Test is typically used to compare the means of two populations. Specifically, it can be 
used to determine whether or not the means in two sample populations are significantly 
different. The probability value (p-value) is compared with the significance level and, if it is 
smaller, the result is significant.  *, **, and *** represent p values of p<0.5, p<0.05 and 
p<0.005, respectively.  
For the calculation of the dose response value Y50, the statistics menu of the Origin 4.1 
program and the logistic non-linear curve fitting for the dose response in pharmacology and 
biology were used.  
 5 RESULTS 
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The first goal of this study was to investigate whether induced heat shock protein expression 
in tumor cells affects antigenicity and immune recognition of a given tumor.  
Of particular interest was the relationship between the intensity of the initial stress and 
changes in tumor physiology and immune competence. Since the  heat shock protein 70 family 
contains members that are constitutively expressed and induced upon heat shock, respectively, 
it was selected for the study. The cellular model was the human melanoma, because it is well 
characterized for antigens and immune recognition by T cells. 
In the first part I have determined the effects of heat treatment on the endogenous presentation 
and processing of tyrosinase and Melan-A/MART-1 and the susceptibility of 624.38-MEL 
cells to immune effector mechanisms.  
The second part of my study addressed the question of extracellular HSP70, as it may occur 
after stress- induced released by dying cells. Because mouse studies pointed to HSPs as 
inducers of tumor antigen specific immune responses (Srivastava 2000), I asked the question 
whether HSP70 can carry the tumor antigen tyrosinase and deliver it to dendritic cells for 
presentation to T-cells, following the mechanismus which is know as cross-presentation.   
5.1 EFFECTS OF HYPERTHERMIA TREATMENT ON TUMOR 
ANTIGENICITY AND SUSCEPTIBILITY TO IMMUNE EFFECTOR 
MECHANISMS 
624.38-MEL cells express tyrosinase and Melan-A/MART-1 antigens and are recognized by 
antigen-specific HLA-A2 restricted CD8+ T-cell clones TyrF8 and A42 respectively, 
indicating that tyrosinase and Melan-A/MART-1 are processed into peptides that bind to the 
class I allotype HLA-A2. The cell line was exposed to heat shock to study the influence of 
two selected thermal doses on antigen expression, processing and presentation via MHC class 
I as well as the ability to induce effector function in MHC class I-restricted T-cells and non-
MHC restricted NK and LAK cells. IFN-g secretion by immune effector cells was used to 
assess the antigen presentation of tyrosinase and Melan-A/MART-1. Cytotoxicity assays were 
performed to determine susceptibility to T-cell- and NK-cell-mediated lysis. Expression levels 
of MHC class I molecules, HLA-A2, tyrosinase and Melan-A/MART-1 antigen were 
determided by FACS analysis, western blot and quantitative RT-PCR. 
5.1.1 Selection of two thermal isoeffect doses in 624.38-MEL cells   
The thermal damage induced by heat is dependent on the magnitude of change in temperature 
and the duration of the elevated temperature. The thermal dose required to induce cell death in 
vitro varies from cell type to cell type and is influenced by microenvironmental factors. In 
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general, exposure of tumor cell lines to temperatures below 42°C leads to a dose-dependent 
cell cycle arrest, but is nonlethal. Higher temperatures (>43°C) for a short time may induce 
the same amount of thermal damage in a given cell type and result in the same survival ability 
(thermal isoeffect dose). Therefore for each cell type it the so-called “breakpoint 
temperature”, which is the critical temperature where cells above this level start to dye 
exponentially, has to be determined. 
The breakpoint temperature for 624.38-MEL cells was determined by exposing cells to 
different temperatures from 41,8°C to 45°C for various time periods ranging from 15 minutes 
to 150 minutes. After heat exposure, cells were seeded at low density and allowed to grow at 
37°C/5% CO2.  After 7 days, the number of colonies was counted and expressed as the 
survival fraction, which is plotted against the duration of heat exposure. Figure 12 shows the 
clonogenic cell survival of 624.38-MEL cells in response to different temperatures. Exposure 
of cells to temperatures below 43,5°C had a minimal impact on their survival, whereas 
temperatures above 43,5°C (44°C and 45°C) exponentially reduced tumor cell survival, thus 
defining 43,5°C as the breakpoint temperature (figure 12). In order to compare the 
immunological consequences of heat treatment of different initial intensity, but with the same 
cytotoxic effect. i.e. the same survival ability, I defined the thermal isoeffect doses (TID) at 
the specified temperature of 41,8°C and of 45°C by adjusting exposure times (120 minutes 
and 22 minutes, respectively). These thermal doses resulted in equivalent clonogenic survival 
rate (isosurvival-rate of 45%).  
Figure 12 
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Figure 12: Clonogenic cell survival of 624.38-MEL cells after heat exposure.  
624.38-MEL cells were exposed to temperatures of 41,8°C/43°C/43,5°C/44°C/45°C for  various time periods up 
to 150 minutes. At intervals of 15 minutes, 624.38-MEL were trypsinized and plated at 100 and 500 cells/T25 
flask and allowed to grow and form colonies in a 37°C/5% CO2 environment. After 7 days cells were fixed, 
stained and colonies were counted. The survival fraction was determined and plotted on a logarithmic scale on 
the y-axis versus the time of heat exposure on the x-axis in a linear scale. 43,5°C was determined as the 
“breakpoint temperature”, defined as the critical temperature where cells above this level start to die 
exponentially. One experiment representative of 3 is shown. 
5.1.2 Thermal dose-related differential kinetics of HSP70 protein expression 
Increased levels of misfolded or aggregated proteins induced by heat shock overwhelm the 
binding capacity of the basal pool of cytosolic molecular chaperones and induce the heat 
shock response. The heat shock response is the time period after heat exposure during which 
expression of heat shock proteins is transcriptionally and translationally upregulated to assist 
in the renaturation or degradation of misfolded proteins (Lindquist 1986) (Welch et al. 1986) 
(Georgopoulos et al. 1993).  
To assess the characteristics of the heat shock response of the melanoma cell line 624.38-
MEL, the cells were treated with the selected thermal isoeffect doses (41,8°C/120 minutes or 
45°C/22 minutes), and the expression levels of HSC70 (constitutive) and HSP70 (inducible) 
were investigated by Western blot analysis and flow cytometry.  
At the physiological growth temperature of 37°C both the constitutively expressed HSC70 
and the inducible HSP70 were detected in 624.38-MEL cells (figure 13A/37°C) by Western 
blot. Heat exposure did not change the expression of the constitutive form of the HSP70 
family (HSC70) but stimulated the expression of inducible HSP70 protein (figure 13A). 
Quantitating HSP70 induction using FACS analysis revealed different kinetics after the two 
thermal doses (figure 13B). For cells heated at 41,8°C/120 minutes, a 4-fold increase HSP70 
was already detected after 4 hours after heat treatment and levels increased linearly to peak 
levels of a 9-fold increase (8,9 ± 0,4) at 48 hours time point (figure 13B, left panel). Cells 
exposed to 45°C/22 minutes showed no increase in HSP70 protein expression after 4 hours of 
recovery. Induction started at the 15 hours time point and reached peak levels of 15-fold 
induction compared to the physiological growth temperature of 37°C (14,9 ± 0,6 at 48 hours) 
(figure 13B, right panel).  
HSP70 protein expression decreased after 48 hours but remained above the pre-heat shock 
level for several days after heat shock (day 7+) (data not shown).  
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Figure 13A 
Figure 13: A) Western blot analysis of HS C70 and HSP70 expression in 624.38-MEL cells: 624.38-MEL 
cells were exposed to 41,8°C for 120 minutes or to 45°C for 22 minutes and then returned to 37°C for 
recovery. Cells were harvested 4, 15, 24 and 48 hours after heat treatment, counted and an equal amount of 
viable cells was lyzed and separated by 10% SDS-PAGE. After electrophoresis, proteins were blotted onto a 
nitrocellulose membrane and stained with antibodies against HSP70 (6B3) or HSC70 (SPA-815). To control 
for equal protein loading, staining for ß-tubulin was performed. The blot is representative of 5 independent 
experiments. 
 
     Figure 13B 
B) Intracellular flow cytometry for inducible HSP70: 624.38-MEL cells were subjected to 41,8°C/120 
minutes (light grey histograms) or 45°C/22 minutes (black histograms) respectively, and harvested at different 
time points after heat treatment. Viable cells were analyzed for intracellular protein levels of HSP70 by 
intracellular flow cytometry using the monoclonal antibody 6B3 and isotype control antibody. Protein 
expression level was calculated as the difference in mean fluorescence intensity (MFI) of 6B3 and the isotype 
control. Fold increase values were calculated using the value at 37°C as a reference value (1 fold, dark grey 
histogram; MFI of HSP70 at 37°C was 47 ± 17). Shown is the mean of 5 independent experiments ( ± standard 
deviations).  
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5.1.3 Thermal-dose related changes in expression levels of immunologically relevant 
proteins: MHC class I, HLA-A2, tyrosinase and Melan-A/MART-1 antigens 
during the heat shock response 
624.38-MEL cells were subjected to 41,8°C for 120 minutes or to 45°C for 22 minutes and 
analyzed for tyrosinase and Melan-A/MART-1 expression at various time points after heat 
shock. Western blot analysis revealed a significant increase in tyrosinase protein levels for 
both thermal doses. The kinetics and expression levels however differed for both doses and 
were similar to HSP70 expression kinetics: tyrosinase protein levels increased linearly after 
exposure to 41,8°C/120 minutes reaching peak levels at 24 and 48 hours, whereas a delayed 
expression and subsequent strong induction was observed after 45°C/22 minutes treatment 
(figure 14A). Tyrosinase expression levels returned to physiological levels after 6-7 days after 
heat shock (data not shown). Interestingly, no significant change in Melan-A/MART-1 protein 
expression occurred during the heat shock response after the two different thermal doses 
(figure 14A). 
Figure 14A 
 
Figure 14: A) Western blot analysis of Melan-A/MART-1 and tyrosinase expression in 624.38-MEL cells . 
624.38-MEL cells were exposed to 41,8°C for 120 minutes or to 45°C for 22 minutes and then returned to 37°C 
for recovery. Cells were harvested 4, 15, 24 and 48 hours after heat treatment, counted and an equal amount of 
viable cells was lyzed and separated by 10% SDS-PAGE. After electrophoresis, proteins were blotted onto a 
nitrocellulose membrane and stained with antibodies against tyrosinase (C-19) and Melan-A/MART-1 (A103). 
To control for equal protein loading, staining for ß-tubulin was performed. The blot is representative of 5 
independent experiments. 
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To determine whether the protein levels correlated with transcript levels, quantitative RT-
PCR for tyrosinase and Melan-A/MART-1 expression was performed (The RT-PCR 
experiments have been performed by Bernhard Frankenberger, GSF-Institute for molecular 
Immunology). There were no significant changes in Melan-A/MART-1 transcripts during the 
recovery period after the two selected thermal doses (figure 14B). As shown in figure 14C, 
tyrosinase transcript level also remained unchanged after treatment of 41,8°C/120 minutes, 
whereas after a thermal dose of 45°C/22 minutes transcript levels dropped to 10% (0,1-fold 
increase, p<0,01) and to 13% (0,13-fold increase, p<0,01) of control levels (37°C=1-fold) at 
15 and 24 hours of recovery. Obviously, the induction in tyrosinase protein did not correlate 
with transcript levels.  
                               Figure 14 B      Figure 14 C 
   
Figure 14: (B) Quantification of Melan-A/MART-1 (b) and tyrosinase (C) transcripts in 624.38-MEL cells. 
624.38-MEL cells were harvested 4, 15, 24 and 48 hours after exposure to 41,8°C for 120 minutes or 45°C for 
22 minutes. Equal amounts of total RNA were analyzed by quantitative real-time RT -PCR using the LightCycler 
system and SYBR green fluorescence. No signals were observed in the negative control (water in place of 
template). Amplification of the house-keeping gene a-enolase was performed in separate capillaries but in the 
same real-time PCR run as the tyrosinase and Melan-A/MART-1 samples to confirm that comparable amounts of 
total RNA were used for all samples. Blotted is the fold-change in transcript levels with the level at 37°C set to 
one (crossing points at 37°C were approximately 13 for Melan-A/MART-1 and 16 for tyrosinase). Values are the 
mean of 3 independent experiments (± SD). The grey horizontal box crossing the bars defines a confidence 
interval in which all values show a difference of ± 1,5 cycles compared to the reference value at 37°C. 
According to the manufacturers´ instructions this cut off interval was defined to discriminate between significant 
overexpression of transcripts from significant underexp ression (0,35 –  2,8). The RT -PCR experiments have been 
performed by Bernhard Frankenberger, GSF-Institute for molecular Immunology). 
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5.1.3.1 Thermal dose-related expression of MHC class I and HLA-A2 molecules  
Due to its essential role in antigen presentation for T-cell recognition the expression of MHC 
class I molecules by tumor cells is the prime determinant for the cellular immunogenicity. 
Tumor cells use the downregulation or loss of MHC class I molecules to escape recognition 
by the immune system (Rivoltini et al. 1995).  
Since tyrosinase and Melan-A/MART-1 are processed into peptides presented by HLA-A2 
(Rivoltini et al. 1995) (Kawakami et al. 1994) (Wolfel et al. 1994) the antibody HB-54 was 
used to specifically detect the HLA-A2 allotype. 
Antibody HB54 showed reduced staining for cells 4 hours after a treatment at 41,8°C/120 
minutes indicating reduced HLA-A2 surface expression. However staining intensity 
recovered and increased above control levels with prolonged recovery times (figure 15, left 
panel; MFI= 669 ± 59 at 72 hours vs 458 ± 92 at 37°C). After treatment at 45°C/22 minutes, 
cells had a more pronounced reduction in surface staining that lasted through 15 hours of 
recovery (figure 15, right panel; MFI= 367 ± 31 at 4 hours; 385 ± 10 at 15 hours vs 458 ± 92 
at 37°C). After 24 hours of recovery, however, expression was increased above control levels 
(MFI= 578  ± 109 at 24 hours vs 458 ± 92 at 37°C) and was maintained at a high level up to 
72 hours of recovery (MFI= 620 ± 22 at 72 hours).  
Figure 15 
Figure 15: Flow cytometry for surface levels of HLA-A2 after heat shock . 624.38-MEL cells were cultured 
at 37°C and exposed to 41,8°C for 120 minutes or 45°C for 22 minutes. Flow cytometry was performed on 
viable cells harvested at 37°C and at different time points after treatment. D  mean fluorescence intensity (MFI) 
was calculated by substracting the mean fluorescence values of the isotype control from the mean fluorescence 
values obtained with the specific antibodies HB54 directed against HLA -A2 molecules. The results represent the 
mean values and standard deviations from 4 independent experiments. 
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Overall class I surface expression as measured using W6/32 antibody, showed similar but less 
pronounced effects (table 3). HLA-A2 mRNA levels remained unchanged after by both 
selected heat treatments (data not shown. Bernhard Frankenberger, GSF-Institute for 
molecular Immunology has performed the RT-PCR experiments). 
 
Table 3A: Thermal isoeffect dose: 41,8°C/120 minutes and sub-sequent recovery at 37°C 
 
 
37°C 4h 
recovery 
15h 
recovery 
24h 
recovery 
48h 
recovery 
72h 
recovery 
D MFI 1 MHC I (W6/32)           427 ± 108 408 ± 166 602 ± 156 706 ± 272 715 ±  234 653 ± 156 
D MFI HLA -A2 (HB-54) 458 ± 92 354 ±131 437 ± 157 511 ± 165 584 ± 169 669 ± 59 
 
Table 3B: Thermal isoeffect dose: 45°C/22 minutes and sub-sequent recovery at 37°C 
 37°C 4h 
recovery 
15h 
recovery 
24h 
recovery 
48h 
recovery 
72h 
recovery 
D MFI 1 MHC I (W6/32)  427 ± 108 333 ± 95 275 ± 64 390 ± 177 463 ± 146 505 ± 75 
D MFI HLA -A2 (HB-54) 458 ± 92 367 ± 31 385 ± 10 578 ± 109 622 ± 75 620 ± 220 
 
1 D mean fluorescence intensity (MFI) was calculated by substracting the mean fluorescence values of the isotype 
control (MOPC21) from the mean fluorescence values obtained with the specific antibodies HB54 directed 
against HLA -A2 molecules or W6/32 directed against MHC class I. MFI of isotype control ranged between 3 
and 25. Results represent the mean values of D MFI and standard deviations from 4 independent experiments 
 
In addition to flow cytometry analysis, the HLA-A2 expression level was determined by its T-
cell  immunostimulatory capacity. JB4 recognizes the HLA-A2 protein itself, independently 
from its bound peptide repertoire and is stimulated to secrete IFN-g. The relative amount of 
IFN-g  produced directly correlates with the expression level of HLA-A2.  
For the stimulation assays low stimulator to effector ratios were selected (5:1, 2,5:1) to ensure 
that the response capacity of JB4 was not saturated. Nevertheless, increased surface 
expression of HLA-A2 did not translate into better T-cell stimulation (compare figure 16 and 
15, 48 and 72 hours after a thermal dose of 41,8°C/120 minutes and 45°C/22 minutes). 
However, less IFN-g was produced when melanoma cells had reduced HLA-A2 staining 
(figure 16; 45°C/22 minutes 4 and 15 hours of recovery p<0,05, N=2; 24 hours of recovery 
p<0,05, N=6). This indicates that even a moderate decrease in HLA-A2 surface expression is 
immunologically relevant, at least for the T-cell clone JB4.  
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Figure 16 
 
Figure 16: IFN-g secretion by JB4 induced by heat-treated melanoma cells . 624.38-MEL cells were 
exposed to 41,8°C/120 minutes or 45°C/22 minutes, harvested after 4, 15, 24, 48 and 72 hours of recovery at 
37°C and cocultured with the CTL clone JB4. A stimulator to effector cell ratio of 5:1 is shown. Similar results 
were obtained at a ratio of 2,5:1 (not shown). IFN-g secretion by JB4 is expressed as percent of IFN-g secretion 
relative to control cells grown at 37°C (absolute values for IFN-g at 37°C at a ratio 5:1 was 703 ± 69 pg/ml for 
JB4); values represent the mean and standard deviations of 6 independent experiments for the time points 24, 
48 and 72 hours and of 2 independent experiments for the time points 4 and 15 hours of recovery at 37°C. * is 
p<0,05 and ** is p<0,01. 
5.1.4 Thermal dose-related endogenous HLA-A2-restricted tyrosinase and Melan-
A/MART-1 peptide presentation 
624.38-MEL cells present the tyrosinase peptide tyr 368-376 (YMNGTMSQV)  and the Melan-
A/MART-1 peptide (AAGIGILTV) via HLA-A2. The tyrosinase-specific CTL clone TyrF8 
and the Melan-A/MART-1-specific CTL A42 were used to test the influence of heat shock on 
the capacity of 624.38-MEL to process and present peptides derived from the antigen 
tyrosinase and Melan-A/MART-1 in the context of HLA-A*0201. This was of particular 
interest since significant changes in tyrosinase expression were observed after heat shock 
(figure 14). Melanoma cells were subjected to 41,8°C for 120 minutes or 45°C for 22 minutes 
and were used to stimulate the TyrF8 and A42 T-cell clones at different time points of 
recovery.  
IFN-g secretion by TyrF8 was decreased when using cells 4 and 15 hours after a heat 
treatment at 41,8°C/120 minutes (p<0,05, N=2). Cells that had recovered for 24 hours 
regained a stimulating capacity comparable to control cells (37°C) (figure 17A). Melanoma 
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cells that had been exposed to 45°C for 22 minutes showed a decreased stimulatory capacity 
for TyrF8 beyond 24 hours (p<0,01 for 4 and 15 hours N=2 and p<0,01 for 24 hours N=6). 
The stimulatory capacity was restored 72 hours after heat treatment (figure 17A).  
IFN-g secretion by A42 cells incubated with heat-treated melanoma cells showed a kinetic 
similar to that of JB4, with a moderate and transient decrease in IFN-g secretion until 24 hours 
of recovery after 45°C/22 minutes (p<0,05 for 4 and 15 hours N=2 and p<0,05 for 24 hours 
N=6) (figure 17B). Obviously, the cells recovered earlier for stimulation of A42 and JB4 than 
for TyrF8. 
The capacity to stimulate IFN-g synthesis did not correlate with HSP70 protein levels (figure 
13 vs 16 and 17) and did not correlate with tyrosinase or Melan-A/MART-1 protein levels. 
Indeed, antigen protein levels increased or stayed constant, respectively, during the entire 
recovery period after the two selected the rmal doses (figure 14 vs 16 and 17). The observed 
reduction in stimulatory capacity at 4 and 15 hours correlated with diminished HLA-A2 
surface expression levels as determined by FACS (figure 11 vs 16 and 17). 
The IFN-g profile of TyrF8 is determined by the combination of HLA-A2 protein and 
tyrosinase mRNA levels. At 4 hours of recovery after both hyperthermic protocols reduced 
HLA-A2 inhibits normal stimulatory capacity despite significant tyrosinase mRNA levels. 
After 15 hours of recovery from 45°C/22 minutes treatment HLA-A2 and tyrosinase mRNA 
were low resulting in low stimulatory capacity. At 24 hours after heat treatment HLA-A2 had 
recovered to the physiological levels. However the remaining impairment in stimulatory 
capacity correlated with very low tyrosinase mRNA levels (figure 14, 15 vs 17A). 
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     Figure 17A 
 
            Figure 17B 
 
Figure 17: IFN-g secretion by TyrF8 (A) and A42 (B) induced by heat-treated melanoma cells . 624.38-
MEL cells were exposed to 41,8°C/120 minutes or 45°C/22 minutes and harvested after 4, 15, 24, 48 and 72 
hours of recovery at 37°C. Viable cells were cocultured with the CTL clone TyrF8 (A) and A42 (B). A 
stimulator to effector cell ratio of 5:1 is shown. Similar results were obtained at a ratio of 2,5:1 (not shown). 
IFN-g secretion by TyrF8 and A42 are expressed as percent of IFN-g secretion relative to control cells grown 
at 37°C (absolute values for IFN-g at 37°C at a ratio 5:1 were 477 ± 50 pg/ml for TyrF8 and 1606 ± 100 pg/ml 
for A42); values represent the mean and standard deviations of 6 independent experiments for the time points 
24, 48 and 72 hours and of 2 independent experiments for the time points 4 and 15 hours of recovery at 37°C. 
* is p<0,05 and ** is p<0,01. 
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5.1.5 Thermal dose-related susceptibility of heat treated melanoma cells to cytotoxic 
effector mechanisms  
Using the T cell stimulation assay and measuring IFN-g produced by antigen specific T cells 
it was observed that the thermal dose (45°C/22 minutes) that induced downregulation of 
HLA-A2 and antigen specific mRNA levels, reduced antigen specific/HLA-A2 complexes on 
the melanoma cell surface. To determine whether the treatment also had an impact on the 
tumor cell susceptibility to cytotoxic mechanisms, a standard 51Cr-release assay was 
performed. 
After a heat shock of 41,8°C/120 minutes there was no significant change in susceptibility of 
melanoma cells to lysis by the three T-cell clones JB4, A42 and TyrF8 over 72 hours of 
recovery, indicating that this thermal dose does not induce resistance to T-cell mediated 
cytotoxicity (figure 14A, B, C left panel). 
The isoeffect thermal dose of 45°C/22 minutes induced temporary resistance to cytotoxic 
effector cells which lasted through 15 hours of recovery time (figure 18A, B, C right panel; 
p<0,01, N=2).  
After 24 hours of recovery the susceptibility of the melanoma cells to lysis by the T cell 
clones JB4 and A42 was restored to control levels, which correlated with restored HLA-A2 
expression in 624.38-MEL cells (figures 15 and 18A and B). For TyrF8, susceptibility to lysis 
after 24 hours of recovery after 45°C/22 minutes was still below control levels, in accordance 
with reduced HLA-A2/tyr-peptide ligand as measured by IFN-g secretion (figure 17A and 
18C). After 48 and 72 hours of recovery after heat exposure susceptibility to lysis dropped 
(with exception of TyrF8). This is in contrast to the stimulatory capacity, to HLA-A2 
expression and antigen expression, all of which had returned to control levels by then. This 
indicates that cytoprotective mechanisms, independent of HLA-class I and antigen expression, 
occur later (after 24 hours) during the recovery from high temperature heat exposure (45°C/22 
minutes), that are not induced by low temperature heat exposure (41,8°C/120 minutes). 
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Figure 18 
 
 
Figure 18: Lysis of heat-treated melanoma cells by the CTL clones JB4 (A), A42 (B) and TyrF8 (C). 
Melanoma cells treated at 41,8°C for 120 minutes or 45°C for 22 minutes were allowed to recover at 37°C for 
4, 15, 24, 48 and 72 hours. At indicated time points adherent, viable cells were harvested and used in a 
standard 5 hour 51Cr release assay at effector to target cell ratios of 10:1, 5:1 and 2,5:1. Shown are the results 
of E:T ratio 10:1. Spontaneous chromium release was below 10% for all time points, except at 4 and 15 hours 
of recovery after both thermal dosages, ranging between 15 and 25%. Lysis values (± SD) were calculated as 
percent of specific lysis at control temperature of 37°C (absolute value of specific lysis at 37°C was 49% ± 4 
for JB4, 19% ± 5 for A42 and 34% ± 12 for TyrF8). 
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Susceptibility towards other immune effector mechanisms were also analyzed. These included 
NK cells and lymphokine-activated killer cells (LAK), which are predominantly T cells. The 
melanoma cell line used is not sensitive to LAK and NK-mediated killing at 37°C and 
treatment employing the two selected thermal dosages did not impact their susceptibility (data 
not shown). Fas surface expression of 624.38-MEL cells before and after heat shock was 
measured by flow cytometry using the antibody APO-1. The levels of Fas surface expression 
was significantly increased from 24 to 72 hours after a heat exposure of 41,8°C/120 minutes 
and 45°C/22 minutes. However, apoptosis was not induced when cells were treated with 
functional anti-CD95 mab (data not shown). 
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5.2 TUMOR-DERIVED HSP70-PEPTIDE COMPLEXES MEDIATE CROSS-
PRESENTATION IN HUMAN DENDRITIC CELLS 
The goal of the second part of the study was to investigate the immunological properties of 
the heat shock protein 70 family members. Once HSPs are released in the extracellular milieu, 
for example as consequence of necrosis, they acquire immunostimulatory properties. 
5.2.1 Purification and characterization of HSP70 from melanoma cell lines 
HSP70 was isolated from human melanoma cell lines, 624.38-MEL, SK-mel 23 and A375-
MEL (see material and methods) and analyzed by silver staining and western blot (figure 11, 
see text in methods). It was observed that HSP70 consisted of both the constitutively 
expressed HSC70 (73 kDa) and the inducible HSP70 (72 kDa) proteins (figure 11, silver 
staining, lane 8). This composition was found to reflect the natural HSP70 expression pattern 
of the melanoma cell lines, 624.38-MEL, SK23-MEL and A375-MEL that were used for 
HSP70 isolation. As demonstrated by intracellular FACS analysis and western blot, these cell 
lines expressed the constitutive HSC70 and the heat inducible HSP70 isoforms at 
physiological growth conditions (figure 19).  
Figure 19 
  
 
Figure 19. Natural expression (at 37°C) of HSP70, HSC70 and tyrosinase by melanoma cell lines, 624.38-
MEL, SK23-MEL and A375-MEL. Intracellular FACS staining was done for 624.38-MEL and A375-MEL 
filled bars: mAb SPA-810, specific for HSP70; and open bars: mAb SPA-815, specific for HSC70). Rat and 
mouse isotype control Abs did not show significant staining for both cell lines (mean fluorescence of 1.4 and 1.1, 
respectively) and were used for reference settings. Depicted on the y-axis is the difference between the mean 
fluorescence of experimental mAb and isotype control (? ?mean fluorescence 1). Error bars indicate s.e.m. 
Expression of HSC70, HSP70 and tyrosinase was also analysed by western  blotting. Gels were run in parallel 
and probed with Abs to HSC70 (SPA -815), HSP70 (HSP-6B3) and tyrosinase (C-19). 
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5.2.2 DCs bind and uptake tumor-derived HSP70-PC  
The binding of HSP70 to DCs and early downstream consequences of binding were analyzed 
by confocal laser scanning microscopy. Immature DCs were incubated for 30 min with Cy5-
conjugated HSP70 at 4°C to exclude endocytosis, or at 37°C to induce uptake. Cy5-labeled 
BSA was used as a negative control. After staining, cells were settled on poly-L- lysine coated 
glass slides, fixed and analyzed for transmission and fluorescence. BSA did not result in 
detectable staining of DCs (figure 20: c, d, g, h, k, l), while all DCs were stained strongly 
positive with HSP70 (figure 20: a, b, e, f, i, j). Different staining patterns were observed at 
4°C and 37°C. At 4°C (figure 20: a, b, e, f), the fluorescence signal was localized to the cell 
surface. In contrast, at 37°C (figure 20: i, j) this surface staining was replaced by a vesicular 
staining at two distinct subcellular locations. Fluorescent signals were localized to perinuclear 
areas and clusters of focal staining near the cell surface, presumably early endosomes.  
Figure 20 
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Figure 20. Receptor -dependent binding of HSP70-PC, uptake and active cell metabolism are required for 
T cell stimulation. (A) Confocal microscopy of immature DCs stained with Cy5-labeled HSP70-PC or Cy5-
labeld BSA at 4°C (surface binding, a-h) and 37°C (uptake, i-l). Cy5-labeled BSA was used for control staining 
(c, d, g, h, k, l). Cells were analysed for fluorescence (shown in yellow) and transmission (shown as overlay with 
the fluorescence signal). Scale bars indicate respective magnifications. Panels a-d represent an overview for the 
staining at 4°C demonstrating that all cells stain positive for Cy5-HSP70-PC and none are positive for Cy5-BSA. 
For presentation purpose fluorescence images for Cy5-BSA stainings (panels c, d, g, h, k, l) are digitally 
enhanced twice to allow detection of residual fluorescence. Individual cells are depicted at higher magnification 
(panels e-l) to visualize discrete staining patterns at 4°C (surface) and 37°C (perinuclear, vesicular) (see text) 
5.2.3 HSP70 from melanoma cells chaperone the tyrosinase peptide and delivers it to 
DCs for MHC-I-restricted cross-presentation 
From physiologic properties as chaperones, HSPs are thought to exist as peptide complexes. It 
was postulated that these peptides lead to antigen-specific T-cell stimulation. To determine 
whether HSP70 isolated from melanoma cells carry melanoma-associated peptides, HSP70 
isolated from two tyrosinase-positive (HSP70-PC/tyr+) and tyrosinase-negative (HSP70-
PC/tyr-) melanoma cell lines, 624.38-MEL, SK23-MEL and A375-MEL, respectively (Riker 
et al. 2000) (Rivoltini et al. 1995) (figure 21A) were incubated with immature DCs from 
HLA-A*0201-positive donors in vitro. If HSP are HSP-PC, than it was expected that antigens 
bound are transferred to DC, which in turn may present them via their MHC class I. MHC 
I/tyr-peptide complexes which can occur on DC surface can be detected with the tyrosinase-
specific CTL clone, TyrF8. 
The experimental procedure was incubation of DC with HSP70-PC, treatement of DC with 
TNF-a to induce maturation and to switch function from antigen uptake and processing to 
presentation. Pulsed DCs were then incubated with TyrF8. If MHC I/Tyr-peptide complexes 
are present than TyrF8 is stimulated to secrete IFN-g, which can be measured by ELISA.  
The results showed that DCs pulsed with HSP70-PC/tyr+ stimulated TyrF8 to secrete IFN-g 
in an HSP70-PC dose-dependent manner (figure 21A, filled squares). IFN-g secretion reached 
a plateau at 600 ng/ml, with a half-maximal value (Y50) of IFN-g achieved at 74.76 ng/ml of 
HSP70-PC/tyr+. The amount of IFN-g secreted was comparable to the maximum stimulation 
obtained using the HLA-A*0201- and tyrosinase-positive melanoma cell line 624.38-MEL 
and SK23-MEL (data not shown). TyrF8 activation was dependent on the HSP70 source. 
HSP70 purified from melanoma cells not expressing the tyrosinase antigen (HSP70-PC/tyr-) 
were unable to stimulate TyrF8 (figure 21A, open squares). IFN-g secretion was further 
dependent on the interaction of both DCs and T cells, since neither DCs alone (figure 21B) 
nor T cells alone (figure 21C) incubated with HSP70 secreted IFN-g.  
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In conclusion, HSP70 transfer antigen specificity of the tumor cells from which they are 
isolated to DC. HSP reflect the antigenic spectrum of the tumor cell since only HSP70 from 
tyrosinase-positive cells transfer tyrosinase to DC. 
Figure 21 
 
Figure 21: HSP70 from melanoma cells chaperone the tyrosinase peptide for MHC class I-restricted cross-
presentation by human DCs. A) Immature DCs (HLA-A*02-positive) were incubated with indicated amounts of HSP70-
PC/tyr+ (from 624.38-MEL cells, filled squares) or HSP70-PC/tyr- (A375-MEL cells, open squares), matured with 
exogenous TNF-a and co-cultured with the HLA-A2-restricted tyrosinase-specific T cell clone TyrF8. Antigen-specific 
stimulation of TyrF8 is demonstrated by the amount of IFN-g secreted. Y50 indicates the amount of HSP70-PC/tyr+ (74,76 
ng/ml) required for half-maximal stimulation of TyrF8. T cell stimulation requires co-culture of T cells with HSP70-PC 
loaded DCs. B) Neither DCs alone C) nor TyrF8 alone secrete IFN-g  after incubation with HSP70-PC/tyr+ (filled squares) or 
HSP70-PC/tyr- (open squares). Five independent preparations of the HSP70-PC from the tyrosinase-positive 624.38 cell line 
and one preparation of tyrosinase-positive cell line SK23-MEL (not shown) were tested for cross-presentation. All 
preparations were tested repeatedly and induced IFN-g  secretion with experimental variations ranging between 500 pg/ml 
and 80 pg/ml of IFN-g at 100 ng/ml of HSP70-PC (not shown). The tyrosinase-negative cell line A375-MEL and tyrosinase-
negative B-LCL were also repeatedly tested and never found to induce significant amounts of IFN-g (not shown). Variations 
in dose-dependency of individual HSP70-PC preparations from tyrosinase-positive melanoma cell lines might be related to 
different purities of the preparations. As determined by silver staining, some HSP70-PC preparations contain other, yet 
undefined proteins, different from HSC70 or HSP70 (not shown).  
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5.2.4 The HSP70-PC mediated cross-presentation of tyrosinase peptide is MHC-I-
restricted  
To confirm that the stimulation of TyrF8 by DCs pulsed with HSP70-PC from tyrosinase-
positive melanoma cells was indeed specific and HLA-A*02-dependent, we performed 
blocking experiments using the anti-HLA-A*02-specific antibody HB54 (see materials). The 
release of IFN-g by TyrF8 was inhibited by pre-incubation of HSP70-PC-pulsed DCs with 
HB54 (p<0.05 at 10 ng/ml of HSP70-PC/tyr+ and p<0.005 at 100 ng/ml of HSP70-PC /tyr+) 
(figure 22).  
 
Figure 22 
 
Figure 22: Stimulation of TyrF8 by HSP70-PC-loaded DCs is HLA-A*02-restricted. IFN-g secretion of 
TyrF8 was measured after co-culture with HSP70-PC/tyr+ (from 624.38-MEL)-loaded DCs in the absence (filled 
bars) or presence (open bars) of anti-HLA-A2 antibody (HB54). p values were calculated for all data, comparing 
IFN-g  values in the presence of HB54 to that in the absence of HB54. ** and *** represent p<0.05 and p<0.005, 
respectively. Data represent the mean IFN-g concentration in pg/ml (mean + s.e.m.) of results from four 
independent experiments. 
 
5.2.5 Active cell metabolism is required for cross-presentation of chaperoned 
peptides and T cell stimulation  
Staining patterns  of DCs incubated with HSP70 at 37°C and at 4°C suggested that HSP70-PC 
after binding to the cell surface was translocated into the cell interior. This suggests that the 
bound peptides might enter the MHC I loading pathway within the cells and not through 
loading on the cell surface MHC. If peptides access via uptake of HSP the MHC I 
intracellular pathway, fixation of DC should abolish this pathway, while peptide loading to 
Antibody Blocking  
IF
N
-g
[p
g/
m
l]
0
100
200
300
400
500
600
700
800
HSP70-PC/tyr+ [ng/ml]
1 10 100
***
**
Isotype Ab
Anti-HLA-A2*02
IF
N
-g
[p
g/
m
l]
IF
N
-g
[p
g/
m
l]
Results 
 82 
surface MHC is still possible. To prove that uptake is a process requiring active cell 
metabolism, immature DCs were fixed with paraformaldehyde (PFA) before being used in 
cross-presentation assays. PFA-fixation completely abrogated T cell stimulation while 
exogenously added tyrosinase peptide was still efficiently presented (figure 23).  
 
 
Figure 23 
 
Figure 23: PFA-fixation of DCs abrogates T cell stimulation. DCs fixed with PFA (1% for 10 min at room 
temperature) were unable to perform HSP70-PC-mediated cross-presentation, but retained the ability to present 
exogenously added tyrosinase peptide (left panel). Untreated DCs are shown in the left panel. 
5.2.6 HSP70-PC-dependent cross-presentation and T cell stimulation do not require 
additional external DC maturation signals 
In general, immature DCs for cross-presentation assays were used because they demonstrated 
strongest binding for HSP70-PC and because they are highly efficient in antigen uptake and 
processing (Banchereau et al. 2000). Based on the rationale that for the process of T cell 
stimulation mature DCs are the most efficient, TNF-a was added exogenously after HSP70-
PC had bound to immature DCs. In the meantime, news results indicated that rh-HSP70 
stimulates secretion of inflammatory cytokines, including TNF-a, from monocytes and DCs 
(Asea et al. 2000) (Asea et al. 2002; Vabulas et al. 2002) and induces maturation of DCs 
(Todryk  et al. 1999; Kuppner et al. 2001; Somersan et al. 2001). Therefore, it was reasoned 
that DCs through binding HSP70-PC might be stimulated to release TNF-a and induce an 
autocrine maturation loop. To investigate whether DCs after incubation with HSP70-PC need 
exogenous TNF-a  for efficient cross-presentation immature DCs were incubated with 
HSP70-PC/tyr+ and either left them untreated (intrinsic DC maturation by HSP70-PC) or 
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gave TNF-a (external DC maturation) before addition of the T cells. As shown in Figure 24, 
cross-presentation by HSP70-PC-treated DCs without exogenously added TNF-a was even 
stronger than that with additional TNF-a. (p<0,005). Polymyxin B, a potent inhibitor of LPS, 
was included in the cross-presentation assay. No inhibitory effect on IFN-g secretion by the T 
cells was observed ruling out the possibility that endotoxin contamination within the HSP70-
PC preparations was responsible for DC maturation and their ability to efficiently stimulate 
the T cells. Immature DCs treated with HSP70-PC only consistently performed better in 
antigen-specific T cell stimulation assay.  
 
Figure 24 
 
 
 
 
 
 
 
 
 
 
Figure 24. HSP70-PC-mediated cross-presentation and T cell stimulation do not require external (i.e.  
TNF-a-induced? DC maturation . Immature DCs were incubated with indicated amounts of HSP70-PC/tyr+ 
(from 624.38-MEL)  and TNF-a was given (external DC maturation signal) (open squares) or was omitted 
(intrinsic, HSP70-mediated, DC maturation) (filled squares) before the addition of T cells. Polymyxin B was 
present in all reactions throughout the cross-presentation assay. TyrF8 stimulation was determined by measuring 
the amount of secreted IFN-g. p values were calculated from data comparing IFN-g values obtained with TNF-a 
to that without TNF-a. ***, p<0.005. 
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The goal of this study was to investigate the function of the tumor-expressed heat shock 
protein 70 family members and to dissect their role in tumor immune recognition as a function 
of intra- versus extracellular location. Another goal was to investigate whether heat-treatment 
at clinically relevant thermal doses affects the immunophenotype of a given tumor, as defined 
by tumor cell sensitivity to immune effector cells. In fact it has been observed that tumor cells 
surviving heat-treatment acquire survival advantage and resistance against subsequent stress. 
This transient resistance has been associated with the induction of intracellular heat shock 
proteins that exert a cytoprotective role. Other studies however, did not observe those effects 
and some even reported increased susceptibility. To understand these contradictory findings at 
a mechanistical level, it is necessary to elucidate when and in what way induced HSPs 
interfere with the immunorecognition of heated tumors. 
 
6.1 EFFECTS OF HYPERTHERMIA TREATMENT ON TUMOR 
ANTIGENICITY AND SUSCEPTIBILITY TO IMMUNE EFFECTOR 
MECHANISMS 
The first part of this study thus addresses the concern that heat shock treatment of tumor cells 
may reduce the presence of tumor antigens, due to heat shock-related reduced transcription, 
translation or protein degradation (Lindquist 1986) (Welch et al. 1986), enabling tumor cells 
to escape immune recognition and immune surveillance. It is already known that during the 
progression of malignant melanoma, changes in antigenic profile occur with concordant loss 
of multiple melanocyte melanocytic differentiation proteins (Slingluff et al. 2000). 
Two doses were selected, which resulted in equivalent clonogenic survival rate and mimic 
those achieved during clinical hyperthermia treatment of tumors. The time-temperature 
dependent effects on tumor antigen expression, processing and presentation by MHC class I 
and on the susceptibility of heat treated cells to antigen specific cytotoxic T cells, NK and 
LAK cells was specifically emphasized. 
The results of this study were that during the heat shock response 1) a dissociation between 
tyrosinase protein and mRNA level occured with a significant increase in tyrosinase protein 
and a parallel decrease in its transcripts. No changes were observed for Melan-A/MART-1. 2) 
T cell recognition did not correlate to changes in antigen protein expression level; 3) 
Melanoma cells maintained the ability to be recognized and to be killed by antigen specific 
CTL clones during the heat shock response after a heat shock of 41,8°C/120 minutes and this 
ability was only transiently decreased after an initial high temperature (45°C/22 minutes).  
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The kinetics and the degree of induction of HSP70 as well as the degree of dissociation 
between tyrosinase protein level and tyrosinase mRNA level correlated with the severity of 
the initial stress (results: figure 13 and 14A vs 14C), demonstrating that these two different 
thermal doses have differential longterm biological effects, even if they have the same 
clonogenic survival ability. This principle recurred in all the results. 
Since tyrosinase protein levels did not correlate with its transcript levels, it was reasoned that 
the mechanism by which tyrosinase protein increased, was a heat-dependent decrease in the 
degradation rate. In amelanotic melanoma cells steady-state tyrosinase (37°C) was found to 
accumulate in the ER; through retrograde translocation from ER into the cytoplasm, 
tyrosinase becomes then a target for proteasome-dependent proteolytic degradation (Halaban 
et al. 1997; Mosse et al. 2001). Furthermore it is known that heat shock blocks the 
translocation of proteins from the ER into the cytosol. This results in ER retention and 
reduced degradation (VanSlyke et al. 2002) providing an explanation for the increased 
tyrosinase level that was observed in the study (figure 25). 
 
Figure 25 
 
Figure 25: The ER retention model. In melanoma cells steady-state tyrosinase (37°C) accumulates in the ER 
as a 70-kDa high mannose glycoform and is translocated into the cytoplasm for degradation in the cytosol; it is 
known that heat shock blocks this reverse traslocation, resulting in a stronger ER retention (Engelhard  et al. 
2002). 
 
At transcriptional level, it is known that severe heat shock blocks RNA splicing and represses 
normal transcription (Yost et al. 1990) providing an explanation for the  observed reduction in 
transcript levels after 15 and 24 hours of recovery after heating melanoma cells to 45°C for 22 
minutes. After a mild heat shock RNA splicing is protected and mature mRNA can 
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accumulate (Yost et al. 1990) which was reflected by the unaltered level of tyrosinase 
transcripts after a heat shock of 41,8°C/120 minutes.  
Surprisingly, no changes in mRNA and protein levels were found for Melan-A/MART-1 
(results: figure 14 B) and HLA-A2. This indicates that not all genes are equally affected. The 
differences may be a reflection of house-keeping genes and constitutive expressed genes 
which are essential for cell survival and may reflect an antigen dominance within the cell.  
The heat- induced quantitative changes of surface expression of MHC class I and allotype 
HLA-A2 were also a function of the initial thermal dose and of the time of recovery after heat 
exposure. Consistent with previous observations that showed an increase in MHC class I 
surface expression 24 and 48 hours after a heat shock of 43°C/60 minutes (cytostatic, sub-
lethal) (Ito et al. 2001) and after 5 days at 39°C (Aboud et al. 1992), this study showes an 
increase in surface expression of MHC class I and HLA-A2 molecules after a heat shock of 
41,8°C/120 minutes. As mRNA levels of HLA-A2 remained constant over time (not shown), 
these changes appear to be translationally or post-translationally regulated, as already 
suggested by others (Aboud et al. 1992). The transient decrease of MHC Class I surface 
expression observed 4 and 15 hours after exposing melanoma cells to 45°C/22 minutes was 
also in agreement with other studies (Blom et al. 1997; Dressel et al. 2000). The transient 
nature of the decrease however has not been described sofar. Indeed surface expression is 
restored already at 24 hours of recovery at 37°C after heat shock (results: figure 15 and table 
3). 
In the B16 mouse model Wells et al. (Wells et al. 1998) correlated the augmentations of 
MHC class I with the level of HSP70 and they observed better antigen presentation. Our 
results did not show a correlation between heat- induced HSP70 overexpression and the 
increase in MHC class I or HLA-A2 surface expression. Neither did we observe that increase 
MHC class I surface expression lead to better antigen presentation. Indeed, in our system 
antigen presentation either remained unchanged (41,8°C/120 minutes) or was transiently 
decreased (45°C/22 minutes) despite an increase in HSP70 expression. One explanation could 
be that the basal level and regulation of both HSP70 and MHC class I are substantially 
different in the mouse and human system. B16 cells have very low basal levels of HSP70 and 
MHC class I and are not efficiently recognized by class I-restricted CTL. Induced 
overexpression of HSP70 after transfection may generate B16 cell clones with higher class I 
expression and better CTL recognition. The human melanoma cell line 624.38-MEL already 
expressed very high levels of MHC class I and HLA-A2 (Rivoltini et al. 1995) and showed 
detectable amounts of the inducible isoform HSP70 at 37°C (results: figure 13A). Increased 
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HLA-A2 surface expression did not lead to increased T cell stimulation, as it might have 
reached a saturation of HLA-A2/peptide complexes on the cell surface. On the contrary a 
slight decrease of HLA-A2 lead to a significantly reduced T cell stimulation. In studying the 
capability to stimulate the tyrosinase specific CTL clone it was observed that the lysability 
response pattern was determined by the combination of HLA-A2 and tyrosinase mRNA, 
supporting the notion that expression of melanoma-associated antigens is a significant co-
factor in addition to MHC class I in determining recognition of melanoma targets (Cormier et 
al. 1999). The observation that mRNA levels and not protein levels of the antigen tyrosinase 
impacts specific T cell recognition is in accordance with recent publications (Kayser et al. 
2003) and supports the DRiPs (defective ribosomal products) hypothesis (Yewdell et al. 1996; 
Schubert et al. 2000). According to Yewdell et al. (Yewdell et al. 1996) antigenic peptides 
may not derive from the native proteins, and are not proportional to the relative abundance of 
this protein.  
While the role of heat shock and of HSP70 overexpression in protecting against T-cell 
mediated lysis is quite controversial, there is a general agreement that heat treatment can 
increase the susceptibility to LAK and NK cells (Jaattela 1990) (Multhoff et al. 1997) 
(Fujieda et al. 1995) (Kubista et al. 2002). Our melanoma cell line 624.38-MEL was not 
susceptible to LAK and NK cells and to Fas-triggered apoptosis irrespective of heat shock 
treatment (not shown), but was susceptible to cytotoxic CTL clones before and after heat 
shock. As a function of the initial thermal dose and of the time of recovery after heat 
treatment, the degree of susceptibility to lysis changed moderately. An early resistance to 
CTL lysis was observed until 24 hours after a heat shock of 45°C/22 minutes. This transient 
resistance was due to a failure in sufficient antigen presentation, as evident in the concordant 
diminished in IFN-g stimulation. However, when HLA-A/peptide complexes were restored on 
the cell surface at 48 and 72 hours after heat exposure, a novel late resistance was detected. 
With the exception of TyrF8, this late induced resistance may be explained by the very high 
expression of HSP70 (almost 15-fold increase), since overexpression of HSP70 has been 
shown to result in resistance to monocytes, cytokines like TNF-a and apoptosis (Sugawara et 
al. 1990; Geginat et al. 1993; Jaattela et al. 1993) (Jaattela 1990; Kusher et al. 1990; Jaattela 
1995; Van Molle et al. 2002).  
6.1.1 Relevance of the first study  
The goal of clinical hyperthermia to reach temperatures which cause cell death is usually not 
achieved homogeneously throughout the tumor. In situ an heterogenous distribution of 
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temperatures is observed, which ranges between 40°C and 44°C. Virtually, the major parts of 
the tumor tissue might be only heated at sub- lethal temperatures. Therefore, the observation 
that tumor cells treated with temperatures below the breakpoint temperature maintain an 
immunological homeostasis during the heat shock response, is of critical importance for the 
clinical application of hyperthermia in the treatment of such tumors. Moreover, the 
observation that important dominant antigens are overexpressed during the heat shock 
response may open a new window of heat application to potentiate antigen expression. 
6.2 TUMOR-DERIVED HEAT SHOCK PROTEIN 70-PEPTIDE COMPLEXES 
ARE CROSS-PRESENTED BY HUMAN DENDRITIC CELLS 
 
The second part of my study addressed the immunological competence of heat shock proteins 
to induce antitumor immunity. In the last years HSPs have been proposed as a tool for cancer 
therapy. They can function as tumor associated activation structures (i.e. HSP70), if detected 
on the surface of tumor cells, thereby activating NK cells (Multhoff et al. 1997) (Multhoff et 
al. 1999) or as antigen-presenting molecules, eliciting a specific T cell response through 
peptides associated in HSP-peptide complexes (HSP-PC) (Srivastava et al. 1994; Tamura et 
al. 1997; Janetzki et al. 2000; Srivastava 2000; Srivastava 2002). 
Using HSP70-PC purified from tyrosinase-positive and tyrosinase-negative melanoma cell 
lines and by focusing on the nature of the APCs that mediate cross-presentation as well as the 
biochemical composition of the tumor-derived HSP70-PC it was possible to demonstrate that 
the immunogenic potentia l of HSP70 as a tool to induce anti-tumor immune responses can be 
extended to naturally expressed, non-mutated human tumor antigens of low immunogenicity 
(Sette et al. 1994). Binding of HSP70-PC to DCs and intracellular events are required for 
HSP70-mediated cross-presentation. Although HSP70-PC bound to immature and mature 
DCs with similar intensity, immature DCs were more efficient in cross-presentation than 
mature DCs (not shown). This makes sense from an immunological point of view, since 
immature DCs are better in antigen uptake than monocytes or mature DCs and have a strong 
capacity to process antigen (Banchereau et al. 2000). Antigen processing ability is potentially 
useful if peptides bind to HSP70 as longer precursors.  
These results demonstrated further that HSP-PC-mediated cross-presentation by immature 
DCs does not require external maturation signals, such as TNF-a. This finding is cons istent 
with previous observations that HSPs represent natural danger signals to the immune system. 
When released by stressed cells (Srivastava et al. 1998) (Chen et al. 1999) they stimulate 
monocytes and dendritic cells to secrete proinflammatory cytokines (TNF-a, IL-12) (Asea et 
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al. 2000) (Asea et al. 2002; Vabulas et al. 2002), and are maturation signals for immature 
DCs (Somersan et al. 2001) (Singh-Jasuja et al. 2000; Kuppner et al. 2001) (Todryk et al. 
1999) (Binder et al. 2000). The results demonstrating efficient cross-presentation without 
external DC maturation signals indicate that the two properties – the chaperoning of antigenic 
peptides and the induction of DC maturation - are intimately linked within tumor-derived 
HSP70-preparations (figure 26). 
 
 
Figure 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Dual function of HSP70 as a chaperone for tumor -derived T cell epitopes and as a signal for 
DC maturation. HSP70 isolated from tissues or cell lines exist as peptide complexes. By binding to DCs the 
peptide cargo is delivered to MHC class I molecules (cross-presentation) and presented on the cell surface for 
recognition by T cells. In parallel receptor-mediated binding induces DCs to mature into efficient antigen 
presenting cells. Therefore, T cells that recognize the MHC class I peptide-complex also receive co-stimulation 
and are optimally primed to evolve into effector cells. (Milani et al. 2002) 
 
A similar conclusion can be reached for gp96 (Zheng et al. 2001). The significance for the 
clinical use of tumor-derived HSP-preparations in stimulating anti-tumor immune responses is 
discussed below.  
The biochemical analysis of HSP70 preparations revealed that they consisted of both the 
constitutively expressed HSC70 and the inducible HSP70. This was found to reflect the 
natural expression pattern of HSP70 and HSC70 in the melanoma cell lines used for HSP70-
PC isolation. Similar constitutive expression of HSP70 has also been described for surgical 
specimens of primary and metastatic human melanoma (Protti et al. 1994). Our previous 
findings that rh-HSP70 but not r-HSC70 is able to deliver the DC maturation signal (Kuppner 
Tumor
HSP70-PC isolated from
tumor tissue
Maturation 
signal
Receptor-dependent 
binding and uptake
Cross-Presentation
MHC class I 
HLA-restricted antigen 
specific T cells
Dendritic cells
T cell stimulation
Figure 1
Discussion 
 91 
et al. 2001) indicate that the heterogeneous composition of tumor-derived HSP70-PC might 
be of functional relevance for the cross-presentation. 
The ability to cross-present HSP-bound antigen has also been shown for APCs other than 
DCs, including monocytes (Castelli et al. 2001) and macrophages (Heath et al. 2001). Using 
blood monocytes, Castelli et al. (Castelli et al. 2001) demonstrated HSP70-mediated cross-
presentation for melanoma antigens other than tyrosinase. However, in their system a much 
higher number of APCs and significantly more HSP70-PC were required for T cell 
stimulation than in our system. Possibly the poor binding of HSP70 to monocytes is one 
explanation for this difference. The studies presented here are of special clinical interest for 
HSP70-based vaccinations. (i) HSP70-PC-mediated antigen presentation by DCs is very 
efficient requiring low amounts (in the nanogram range) of HSP70-PC (results: figure 21) 
(Srivastava 2000). This can be explained by the receptor-mediated uptake for HSP70-PC 
versus fluid phase uptake and surface peptide exchange mechanisms for exogenous peptides, 
respectively. In addition, Binder et al. (Binder et al. 2001) described that HSP70 positively 
influences cross-presentation of chaperoned peptides by efficiently directing them to an 
ER/Golgi compartment where loading onto the MHC class I molecules occurs. The 
observation that an ER/Golgi localization is important for efficient cross-presentation is 
consistent with the confocal microscopic data that show a perinuclear staining of immature 
DCs incubated with Cy5- labeled HSP70-PC at 37°C (results: figure 20). An additional 
explanation for the efficacy of HSP-preparations to induce anti-tumor immune responses 
might be related to the dual function of HSPs delivering antigen and inducing DC maturation. 
Linking these two properties is one possibility to ensure that antigen presentation occurs in an 
environment optimal for T cell stimulation. (ii) Initial vaccination studies using murine tumor 
models demonstrated that the anti-tumor immunity achieved by vaccination with gp96 or 
HSP70 preparations is restricted to the tumor from which the gp96/HSP70 was isolated 
(Srivastava et al. 1994) (Srivastava 2000). HSP-based vaccination strategies are therefore 
considered patient-individual treatment modalities. This view is challenged by our 
observation, and that of Castelli et al. (Castelli et al. 2001), demonstrating that HSP70 
isolated from human melanoma cells chaperone naturally expressed non-mutated and shared 
human melanoma antigens and transfer them to APCs for T cell recognition. If cross-
presentation of shared human tumor antigens by HSP70-PC followed by efficient T cell 
stimulation is routinely achieved with HSP70-PC the clinical application of HSP70-based 
vaccines may be extended from a patient- individual treatment to use in an allogeneic 
vaccination setting. (iii) This novel insight into the mechanistic events responsible for HSP70-
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mediated cross-presentation by DCs are of additional interest for treatments involving 
hyperthermia.  
 
6.3 WORKING HYPOTHESIS OF HYPERTHERMIA 
The biological rationale for the use of hyperthermia in the treatment of cancer is based on the 
observation that temperatures above 42°C are cytotoxic to tumor cells as a function of time. 
Cytotoxicity is high for radioresistant S-phase cells and for cells nutritionally deprived and 
acidotic (in the region of tumor with many radioresistant hypoxic cells). Heat has also been 
shown to be a radiosensitizer and a chemosensitizer (Stewart et al. 1984). 
Hyperthermia was found to be effective in clinical trials if integrated in a loco-regional 
treatment strategy for certain solid tumors, like melanoma (Overgaard et al. 1995), soft tissue 
sarcomas and tumors of the bone, cervix and rectum, head and neck cancers as an adjuvant to 
radiation and chemotherapy (Falk et al. 2001). Besides its direct cytotoxic effect on tumor 
cells, immunologically relevant changes in tumor cell physiology occur after heat shock 
treatment. Based upon the observations that HSP70-peptide complexes chaperone antigenic 
peptides and deliver them to DCs in an immunogenic way resulting in efficient T-cell 
stimulation, and that the tumor itself remains susceptible to immune effector mechanisms 
during the heat shock response, the following chain of events may be proposed (figure 27).  
HSP70 can be expressed on the cell surface of some tumor cells and act as an activator of NK 
cells (Multhoff et al. 1997) (Multhoff et al. 1995; Multhoff et al. 1996; Multhoff et al. 1999). 
During clinical hyperthermia peak temperatures may reach up to 42°C inducing HSP70 
upregulation (Fuller et al. 1994). Within this temperature range local necrosis occurs resulting 
in the release of HSPs (Melcher et al. 1998) (Basu et al. 2000),  uptake by DCs and 
subsequent processing and presentation of associated peptides (Todryk et al. 1999). Surviving 
tumor cells during the heat shock response maintain the ability to be recognized and killed by 
immune effector mechanisms. Since HSP70-mediated cross-presentation is efficient without 
additional DC maturation signals an environment optimal for T cell stimulation is ensured. 
The proposed dual role of HSP70 as a chaperone for antigenic peptides and as a signal for DC 
maturation then leads to efficient priming of circulating T cells. Therefore, upregulating 
HSP70 expression or other stress proteins (e.g. HSP110 and grp170) (Wang et al. 2001) and 
causing local necrosis (Melcher et al. 1998) by heating the tumor tissue has the potential to 
directly activate the immune system against tumors (“vaccination in situ”).  
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Figure 27 
 
 
Figure 27: Working hypothesis for hyperthermia. (1) Clinical hyperthermia (heat shock) upregulates HSP70 
expression in tumor tissues. (2) HSP70 surface expression may occur in some tumor cells activating NK cells. 
(3) Due to induction of local necrosis, HSP70 and HSP70-PC can be released (4) HSP70-PC bind to APCs and 
induce cytokine secretion, APC activation, and in parallel deliver the peptide cargo into the cross-presentation 
pathway for MHC class I restricted presentation and antigen specific T cell activation (6). (7) Tumor cells 
remain susceptible to lysis from specific activated T cells (immunological homeostasis). 
APC
NK cellsTumor
HSP70-PCHeat Shock
Stimulation
Proliferation
CTL
HSP70
1
2
3
4
5
6
7
Immunological 
homeostasis
 7 SUMMARY 
Summary 
 95 
The goal of this study was to investigate the function of the heat shock protein 70 family 
members, expressed in tumors under physiological and stress conditions and to dissect their 
role in tumor immune recognition as a function of intra- versus extracellular location. Another 
goal was to investigate whether heat-treatment at clinically relevant thermal doses affects the 
immunophenotype of a given tumor, as defined by tumor cell sensitivity to immune effector 
cells.  
For these questions, the human melanoma system was selected because it is well 
characterized with regards to tumor-associated antigens, like tyrosinase and Melan-A/MART-
1, their epitopes and restriction elements for MHC class I presentation.  
In the first part of the study the focus specifically was on the time-temperature dependent 
effects of heat exposure. Two different thermal doses (41,8°C/120 minutes and 45°C/22 
minutes) were selected that mimic the heterogeneity of the achieved temperature distribution 
within the tumor and the time-temperature dependent changes were determined in: a) antigen 
expression (tyrosinase and Melan-A/MART-1) at the protein and mRNA level; b) expression 
of the inducible HSP70 and the constitutive HSC70; c) processing and presentation of 
tyrosinase and MART-1 via MHC class I; d) susceptibility of melanoma cell lines to cytotoxic 
T lymphocytes like CD8+ T cells, LAK and NK cells. It was demonstrated that HSP70 and 
antigen expression display distinct expression and kinetics that reflect the thermohistory of 
the cells, i.e. exposure to high or low thermal doses. Immunologically, a low thermal dose did 
not alter immune recognition of the cells despite the fact that intracellular HSP70 and 
tyrosinase protein were upregulated. High thermal dose induced a pleiotropy of effects, 
including stronger upregulation of HSP70 and tyrosinase protein but downregulation of 
tyrosinase at mRNA level. Concordant with reduced HLA-A2 surface expression and 
tyrosinase mRNA levels, immune recognition of the heat-treated cells was initially reduced, 
but pretreatment levels were restored after 72 hours of recovery. The observation that tumor 
cells treated with temperatures below the breakpoint temperature maintain an immunological 
homeostasis during the heat shock response is of critical importance for the clinical 
application of hyperthermia in the treatment of tumors.  
In the second part of the study, the ability of HSP70 to cross-present a naturally expressed 
human tumor antigen, tyrosinase, that is of low immunigenicity, a situation that more closely 
resembles the patient situation was investigated. It was demonstrated that HSP70-peptide 
complexes (HSP70-PC) purified from tyrosinase-positive (HSP70-PC/tyr+) but not from 
tyrosinase-negative (HSP70-PC/tyr-) melanoma cells deliver the tyrosinase antigen to 
immature DCs for MHC class I restricted T cell recognit ion. T cell stimulation by HSP70-
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PC/tyr+ incubated with immature DCs with was very efficient even without additional DC 
maturation signals (e.g. exogenous TNF-a) demonstrating the ability of tumor-derived 
HSP70-PC to act as a chaperone for peptides and a signal for DC maturation. HSP70-PC in 
exerting both functions on DCs, delivering antigens and maturing DCs, ensures that the 
peptides that are delivered to the DCs are presented in an immunogenic context optimal for T 
cell stimulation.  
In conlusion, induction of intracellular heat shock proteins (HSPs) by heat does not interfere 
with the tumor immune recognition and when HSPs are expressed extracellularly they acquire 
immunostimulatory properties. These observations open new perspectives for the application 
of hyperthermia in combination with HSP-based vaccine in the treatment of solid tumors.  
 8 ZUSAMMENFASSUNG 
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Das Primärziel dieser Arbeit war, die Funktion von Hitzeschockproteinen (HSP) der Familie 
70, die entweder konstitutiv exprimiert oder unter Stressbedingungen induziert werden, zu 
untersuchen. In diesem Zusammenhang sollte vor allem ihre Rolle in der anti- tumoralen 
Immunantwort in Abhängigkeit von ihrer intra- oder extrazellulären Lokalisation analysiert 
werden. Ein weiteres Ziel war, den Einfluss einer Hyperthermiebehandlung auf den 
Immunophänotyp des Tumors zu untersuchen, welcher durch die Tumorsensitivität gegenüber 
Immuneffektorzellen definiert wird.  
Um diesen Fragestellungen nachzugehen, wurde das humane Melanomsystem gewählt, da 
zahlreiche tumorassoziierte Antigene, wie zum Beispiel Tyrosinase und Melan-A/MART-1, 
sowie Epitope und Restriktionselemente bekannt sind. 
Im ersten Teil wurde insbesondere auf die Zeit- und Temperatur-abhängige Wirkung von 
Hitzeschock fokussiert und hierfür wurden zwei unterschiedliche Hitzedosen (41,8°C/120 
Minuten und 45°C/22 Minuten) gewählt, welche die intratumorale Hitzeverteilung in vivo 
nachahmen. Insbesondere wurden die Zeit- und Temperatur-abhängigen Veränderungen in a) 
der Antigenexpression von Tyrosinase und Melan-A/MART-1 auf mRNA- und Proteinebene; 
der b) der Expression des konstitutiven HSC70 und des induzierbaren HSP70; c) 
Antigenprozessierung und -präsentation über MHC Klasse I und d) der Suszeptibilität der 
Melanomzelllinien gegenüber zytotoxischen T-Zellen wie CD8+, LAK und NK Zellen, 
untersucht. Es zeigte sich, dass HSP70 und die Antigen-Expression eindeutig unterschiedliche 
Kinetiken aufweisen, welche die „Thermohistorie“ der Tumorzellen widerspiegeln. Nach 
immunologischem Gesichtspunkt beeinträchtigte eine niedrige Hitzedosis die 
Immunerkennung der Tumorzellen nicht, obwohl sowohl das intrazelluläre HSP70 als auch 
das Tyrosinase-Protein stark heraufreguliert wurden. Bei höherer Hitzedosis hingegen wurden 
verschiedenartige Effekte beobachtet, darunter eine starke Hochregulation des HSP70 und des 
Proteins-Tyrosinase, aber auch eine Herabregulation der Tyrosinase-mRNA. Die 
Immunerkennung der hitzebehandelten Tumorzellen war zunächst herabgesetzt, was durch 
die vorübergehende Reduktion der HLA-A2 Oberflächenexpression wie auch durch die 
geringere Tyrosinase-mRNA erklärt werden kann. Diese transient reduktierte 
Immunsensitivität war reversibel und wurde innerhalb von 72 Stunden wiederhergestellt. Die 
Beobachtung, dass mit niedrigen Hitzedosen behandelte Tumorzellen eine immunologische 
Homöostase erhalten, ist von entscheidender Bedeutung für die klinische Anwendung der 
Hyperthermie.  
Im zweiten Teil wurde die Fähigkeit von HSP70 untersucht, Tyrosinase-Peptide in den Cross-
präsentationsweg von DZ zu vermitteln. Tyrosinase ist ein natürliches, nicht-mutiertes 
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humanes Tumorantigen, welches wenig immunogen ist. Dies ist eine Konstellation, die der 
Patientensituation ähnelt. Es konnte nachgewiesen werden, dass DZ, die mit HSP70-PC aus 
Tyrosinase-positiven Zell-Linien (HSP70-PC/Tyr+) beladen wurden, eine 
konzentrationsabhängige Stimulation des Tyrosinase-spezifischen T-Zell Klons zeigten. Zur 
Stimulation war ein zusätzliches „Maturierungssignal“ wie z.B. TNF-a nicht nötig, was 
beweist, dass HSP70-PC die Eigenschaft besitzen, antigene Peptide in den Cross-
präsentationsweg zu vermitteln und DZ auszureifen. In ihrer dualen Funktion, als Vermittler 
für Tumorantigene an DZ und als Gefahrsignal für die Ausreifung von DZ, führen HSP70-PC 
zu einem effizienten „Priming“ zirkulierender T-Zellen und zur Induktion einer anti-
tumoralen Immunantwort.   
Zusammenfassend konnte gezeigt werden, dass die Induktion von intrazellulären HSP durch 
Hitzeschock nicht mit der Immunerkennung des Tumors interferiert und dass HSPs, die sich 
im extrazellulären Milieu befinden, immunostimulatorische Eigenschaften erwerben. Diese 
Beobachtungen eröffnen neue Perspektiven für die Anwendung der Hyperthermie in 
Kombination mit HSP-basierten Vakzinen bei der Behandlung solider Tumore.   
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